

TAKING TEXAS TOBACCO FREE

Implementing a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control within Behavioral Health Settings A Step-By-Step Guide



HEALTH Research Institute

Helping Everyone Achieve a LifeTime of Health

HOUSTON

COLLEGE OF EDUCATION

Psychological, Health, & Learning Sciences





Cancer Prevention & Research Institute of Texas This step-by-step *Implementation Guide* reflects experience gained through previous evidence-based cancer prevention projects funded by the Cancer Prevention & Research Institute of Texas [CPRIT; PP130032 (PI: Drs. Lorraine R. Reitzel & Cho Y. Lam), PP160081 (PI: Dr. Lorraine R. Reitzel), and PP170070 (PI: Dr. Lorraine R. Reitzel)]. The development of this *Implementation Guide* was funded by CPRIT grant #PP200051 (PI: Dr. Lorraine R. Reitzel) that focuses on the dissemination and implementation of the Taking Texas Tobacco Free Education/Training Program for Personnel Addressing Tobacco Control within organizations treating individuals with behavioral health needs (i.e., mental and substance use disorders).

This work would not be possible without the co-leadership of our community partners, Integral Care of Austin, Texas, our academic partners from the University of Houston, and many, many strong advocates and stakeholders at the behavioral health and substance use disorder treatment centers with whom we worked. In particular, we are grateful for the collaboration of the 3 local mental health authorities with whom we piloted this program, West Texas Center for MHMR, Border Region Behavioral Health Center, and Heart of Texas Region MHMR Centers for partnering with us in developing and improving this training program. The contents of this *Implementation Guide* are solely the responsibility of the University of Houston and Integral Care authors and do not necessarily represent the official views of the project supporters. More information on the program described herein can be found on the TTTF website: www.TakingTexasTobaccoFree.com.


Thank you



Acknowledgements	<u>3</u>
Introduction to the Taking Texas Tobacco Free Program	<u>6</u>
Implementation Components of Taking Texas Tobacco Free	<u>9</u>
Building and Embedding Center-based Expertise to Sustain Tobacco Control Efforts	<u>10</u>
Introduction to the Components of the TTTF Sustainable Education/Training Program	<u>12</u>
The TTTF Sustainable Education/Training Program	<u>14</u>
Tips on Delivering the TTTF Training Program Online	<u>14</u>
Component 1: Comprehensive Training of Center Program Champions	<u>16</u>
Assessments and Tools	<u>18</u>
Component 2: Development of Tailored Evidence-Based Tobacco Education Curriculum	<u>19</u>
Assessments and Tools	19
Component 3: Practice Trainings Sessions—Training and Assessment	<u>20</u>
Assessments and Tools	<u>21</u>
Component 4: Delivery and Assessment of Actual Instruction to Center Employees	<u>22</u>
Assessments and Tools	<u>23</u>
Component 5: Integration of Regular Tobacco Education into New Employee Trainings, Annual Employee Trainings, and In-service Trainings	<u>24</u>
Ongoing Training	<u>24</u>
Tobacco Treatment Medication Availability	<u>26</u>
Frequently Asked Questions	<u>28</u>
Bibliography	<u>30</u>
Appendices	<u>32</u>

TABLE OF CONTENTS





INTRODUCTION TO THE

TAKING TEXAS TOBACCO FREE PROGRAM (TTTF)

WHAT IS TTTF?

Taking Texas Tobacco Free (TTTF) is an evidence-based organizational-level intervention funded by the Cancer Prevention & Research Institute of Texas that provides practical advice, technical assistance, consultation, education, training, and treatment resources to mental/behavioral health and substance use disorder treatment centers throughout the state of Texas. https://www.takingtexastobaccofree.com

The mission of TTTF is promoting wellness among Texans by partnering with healthcare organizations to build capacity for system-wide, sustainable initiatives that will reduce tobacco use and environmental tobacco smoke exposure among employees, service consumers, and visitors.

TTTF works with organizations that serve consumers with mental health and/or substance use disorders.

This includes marginalized subgroups with high rates of smoking and other tobacco use, including those experiencing homelessness, identifying as members of a sexual minority, who are disadvantaged single mothers, criminal justice-involved, and who are of lower socio-economic status. TTTF assists centers to implement a multi-component tobacco free workplace program that includes: 1) tobacco free workplace policies banning all tobacco products, including chewing or smokeless tobacco and e-cigarettes or electronic nicotine delivery systems (ENDS); 2) education to all employees; 3) the integration of tobacco use assessments (e.g., tobacco use screenings) into routine practice; 4) training of clinicians (i.e., direct service clinicians) on evidence-based tobacco use cessation services and their provision to employees and consumers; and 5) a community engagement and outreach component. On our website https://www.takingtexastobaccofree.com, we provide detailed information on implementing each of the 5 TTTF program components within our *Implementation Guides*. Both *Implementation Guides* can be found under TOOLS: *Implementation Resources, Taking Texas Tobacco Free Implementation Guide for Behavioral Health Settings* and *Taking Texas Tobacco Free Implementation Guide for Substance Use Treatment Centers*.



WHY FOCUS ON BEHAVIORAL HEALTH CENTERS?

The focus on organizations treating individuals with mental and behavioral health needs is critically important to cancer prevention because these individuals: 1) comprise 21% of the population but represent approximately 44.3% of the tobacco market¹; 2) account for as many as 50% of annual smoking-related premature deaths²; 3) experience cancer incidence that is 70% higher than the general population predominately due to tobacco use³⁻⁶; and 4) despite the existence of effective treatments and overall decline in tobacco use among the general population, have smoking rates that have remained relatively static over time, suggesting that they benefit less from existing tobacco control interventions than other tobacco users.²⁻⁶ Organizational-level interventions are necessary to affect tobacco use rates among subgroups experiencing tobacco-related disparities because they yield greater reach with enhanced cost-effectiveness relative to individual-level treatments.^{19,11} Therefore, evidence-based tobacco free workplace programs like TTTF have the potential to make a significant impact on the prevention of tobacco-related cancers among individuals with mental or behavioral health needs and those who serve them.

Individuals with Mental & Behavioral Health Needs

REPRESENT ABOUT

44.3%

OF THE TOBACCO MARKET

ACCOUNT FOR

~50%

OF ANNUAL
SMOKING-RELATED
PREMATURE DEATHS

70%

HIGHER THAN
THE GENERAL
POPULATION

LOW

DECLINE OVER TIME
DESPITE DECLINE IN
GENERAL POPULATION

ARE TOBACCO FREE POLICIES EFFECTIVE?

Comprehensive tobacco free workplace programs are multi-component programs that include a tobacco free workplace policy as well as attention to the identification and treatment of tobacco users through clinician training/education and the implementation of regular screening and treatment/referral policies/procedures. Tobacco free workplace policies that completely prohibit the use of tobacco and other nicotine delivery products on worksite property alone are an effective means in reducing tobacco use and dependence.¹² For example, smokers employed in workplaces with complete smoking bans are more likely to consider quitting and quit at higher rates than those employed at workplaces with partial or no bans.¹³ The implementation of tobacco free workplaces, particularly when coupled with the provision of tobacco use cessation resources, may also reduce smoking rates among those who continue to smoke.¹³ Additional benefits include reduced absenteeism, reduction in smoking-related fires, increases in employee productivity, averted medical costs,¹⁴ sustenance of cessation through the elimination of tobacco cues, and a reduction in exposure to environmental tobacco smoke among non-smokers.^{12,13}



HOW DOES TTTF WORK?

TTTF was adapted from a comprehensive tobacco free workplace program previously implemented within Integral Care, one of the 39 Local Mental Health Authorities serving individuals with behavioral health needs in Texas, and was guided by recommendations for comprehensive tobacco control programming. 15,16 TTTF was specifically designed to increase the capacity for and the provision of evidence-based interventions for tobacco use in behavioral health settings because the delivery of evidence-based interventions is known to increase guit attempts and cessation. 16 TTTF program components were designed to address consumer-level, center-level, and community-level barriers and thereby meet the need for evidence-based service provision within the targeted settings. Primary program components entailed tobacco free workplace policy implementation and enforcement (center-level); employee education about tobacco use hazards (employee-level); clinician training to regularly screen for and address tobacco dependence via intervention (clinician-level); and community outreach to address and prevent tobacco use more broadly (community-level); each of these components impact consumer-level tobacco cessation services (consumer-level). These are further explicated in Figure 1. To maximize buy-in at the targeted settings, we used a toolkit-based approach to facilitate center, employee and clinician, and community-level changes in how tobacco use was being addressed, which allowed stakeholders in these settings to identify their needs at each level and select evidence-based strategies for best addressing them within their context.




Figure 1.

Major Components of TTTF and How They Address Barriers at Behavioral Health Centers



DOES TTTF WORK?

As of 2022, TTTF has been implemented within 22 local mental health authorities across Texas, 15 substance use treatment centers, and 9 community agencies, representing almost 302 individual treatment "centers" covering over half the state of Texas. We have trained over 14,000 professionals in over 276 training sessions and reached over 710,370 individuals with our program materials. Our professional publications and more information about TTTF's successes can be obtained online https://www.takingtexastobaccofree.com articles or by contacting the team directly via the website.



BUILDING & EMBEDDING CENTER-BASED EXPERTISE TO SUSTAIN TOBACCO CONTROL EFFORTS

A cornerstone of TTTF implementation has been the provision of education to all employees and clinicians at participating agencies on evidence-based practices for treating tobacco dependence within behavioral health settings, because education is the foundation for changing how employees and clinicians address tobacco use among the consumers in their care.

While TTTF team members delivered a tobacco education/training curriculum to clinicians and employees at participating behavioral health centers in our prior grants PP130032, PP160081, and PP170070, our program partners reported they lacked the necessary training and materials to sustain ongoing in-house educational/training efforts.

Research shows that lack of education or training on how to treat tobacco dependence is the biggest barrier to providing tobacco treatment. Given the high employee turnover in behavioral health centers, it is essential to ensure continuous, in-house expertise in effective tobacco treatment through establishing an ongoing tobacco education training program. As provision of education on each core program component is essential to successful program implementation and sustainment, we responded to this gap in the TTTF program by developing an evidence-based tobacco control training curriculum and program.

The TTTF Sustainable Education/Training Program is a "Train the Trainer" program. Our goal is to increase the reach, adoption, and effectiveness of evidence-based tobacco cessation interventions within behavioral health treatment settings through the development, dissemination, and implementation of a curriculum and training program. This program is intended for use by "program champions" within these settings. The program champion is a center employee, usually a clinician or manager, who is trained in treating tobacco dependence and is responsible for training others in their center in tobacco education and treatment. The aim of this "Train the Trainer" program is to facilitate long-term, competent, center-led delivery of employee and clinician education about evidence-based practices for tobacco control through New Employee, Annual, and In-service Trainings. Developing local center program champions as tobacco education trainers will ensure that embedded expertise on evidence-based practices for tobacco control is not jeopardized over time through employee turnover.




PILOTING THE PROGRAM

Three local mental health authorities, who had previously successfully adopted the TTTF program into their centers, partnered with us on piloting this Train the Trainer program. Through their collaboration and guidance, we developed curricula, program materials, and this Implementation Guide. Through their partnership, this training program has successfully: 1) developed and trained program champions who can confidently deliver evidence-based tobacco training to their center employees and clinicians; 2) provided participants with a curriculum adjustable to their center's needs; 3) trained center stakeholders on how to educate others through delivering center-led trainings; 4) provided technical assistance to ensure the establishment of a long-term training initiative for new employees/clinicians or continuing education for existing employees/ clinicians; and 5) developed and made the training curriculum available online for other centers interested in implementing this training program. The piloting of this training program has been successful: participating local mental health authorities have increased their capacity to facilitate sustainable, competent, center-led education in behavioral health settings to address the problem of tobacco use and dependence among individuals with behavioral health needs, and are now regularly providing on-site trainings.



Program Successes Through Collaboration & Guidance













IMPLEMENTATION COMPONENTS OF THE TTTF SUSTAINABLE EDUCATION/ TRAINING PROGRAM

Implementation of the training program occurs in phases that include formative evaluation – exploring the needs and characteristics of a center to develop and fit the training program accordingly, center preparation, active program implementation, and sustainment. Stakeholder feedback collected during each phase should guide implementation efforts.

Our training program includes the following main components: 1) selection and comprehensive training of center program champions, who will become trainers and deliver tobacco education/trainings to center employees;

2) development of an evidence-based tobacco education curriculum, tailored to needs and length (generally ~60-90 minutes) of individual centers; 3) training of program champion(s) on delivery of tobacco education curriculum via mock practice training sessions with other champions/peers, including constructive feedback/evaluation forms developed by TTTF; 4) delivery of the tobacco education curriculum by program champion(s) to actual center employees, assessed by at least 2 peer observers; and the 5) integration of regular tobacco education into New Employee Trainings, Annual Employee Trainings and In-service Trainings.

Each of the aforementioned main components represent different phases of training, each of which involves observation and assessment of trainers by peers using assessment tools developed by the TTTF team. Train the Trainer materials and tools are located within this *Implementation Guide* and available online on our program website for free: https://www.takingtexastobaccofree.com/trainthetrainer. Additional tobacco education and dissemination materials (e.g., posters, rack cards and quit cards) are available for free download on our home page in various languages including English, Spanish, Chinese, Vietnamese, Farsi and Japanese, at: https://www.takingtexastobaccofree.com.



THE PURPOSE OF THE IMPLEMENTATION GUIDE


The purpose of this *Implementation Guide* is to share the TTTF Training Program with non-participating behavioral health centers and the broader public, and to offer step-by-step guidance for its implementation in other settings. On the following pages, the reader will find our recommendations, field-tested training curriculum and evaluation materials, and several appendices developed through our work in disseminating and implementing the TTTF Training Program across Texas. Should you need further guidance on implementing the TTTF Train the Trainer program, please contact our program manager, Bryce Kyburz, at Bryce.Kyburz@integralcare.org.

While the implementation of the TTTF Train the Trainer program is not dependent upon the adoption of a comprehensive tobacco free workplace program, we strongly encourage behavioral health centers that are interested in effectively treating tobacco dependence to consider adopting such a comprehensive approach to tobacco control. For more information on developing and implementing a comprehensive tobacco free program within behavioral health or substance use treatment centers, please see our other step-by-step *Implementation Guides*, available on our webpage: https://www.takingtexastobaccofree.com.

We have organized this *Implementation Guide* roughly by each component of the training program, as each component is implemented in a sequential manner. All components are important and attending to each will increase the impact that your center can have on addressing tobacco use and preventing cancer among your consumers. We are exceedingly pleased to share our experiences with you and are available to your center should questions arise during your tobacco free journey.

Sincerely,

The TTTF team



THE TTTF SUSTAINABLE EDUCATION/TRAINING PROGRAM

TIPS ON DELIVERING THE TTTF TRAINING PROGRAM ONLINE

The entire TTTF Education and Training Program has been designed to be delivered online, in-person, or a hybrid of the two, depending on center employees' preferences and accommodations regarding safety concerns during the COVID-19 pandemic. For your convenience, we have included a "TTTF General Video Conferencing Platform Training Instructions" (Appendix A), that provides detailed technical instructions on using Zoom and Microsoft Teams. Here, we describe best practices for presenting with Zoom to assist trainers in delivering a smooth and effective training experience for all.

PREPARE YOURSELF

The first thing you must do as a good presenter, whether online or in a live classroom, is prepare yourself.

- Reduce distractions in your physical space by removing anyone or anything that may distract you.

 Consider moving your cell phone to another room and unplugging the land line (if you still have one).

 If there are other people or pets in your home, have a plan in place for mitigating interruptions.
- Remove visual clutter from your background. A messy closet or unfolded laundry behind you may distract your attendees. Even a neat shelf with mementos or books can be distracting.
- Make sure your materials are readily available. Consider creating one folder on your desktop for all your presentation-related materials so you are not fumbling around during the session.
- Practice your presentation ahead of time, preferably numerous times. Seamless transfers between
 a PowerPoint slide, other documents, and your own image can help the attendees focus on
 your message, rather than on your technical skills.

PREPARE YOUR VIRTUAL SPACE

Presenting in a virtual environment requires a bit of juggling and a good amount of technical fluency. However, you do not have to be a technical wizard to present online. There are many things you can do to prepare your virtual space so that you present your best self to an audience.

• Have a Zoom buddy who can take care of the technical details that arise before and during your presentation.

Online, the potential problems that audience members might have—difficulty logging in, problems with the audio, inability to see a shared screen (we could go on and on)—are numerous, and the presenter cannot solve them all. A Zoom buddy can work through these issues while you continue your presentation.



- Check your Zoom settings. Make sure that you have enabled any features that you will need during the course of your presentation such as <u>file sharing</u>, <u>nonverbal feedback</u>, <u>sound notifications</u>, <u>waiting rooms</u>, and <u>allowing participants to join before the host</u>.
- Adjust your webcam so that you appear present and engaged. Remember that if you are looking at your webcam,
 the audience will perceive that you are looking at them. Face your camera at all times. If you find your eye wandering to your own video, try pinning the video of a specific attendee top and center and looking at that attendee's
 video; each individual will perceive that you are looking at them.
- Make sure you close other applications that may make distracting noises during your training (e.g., a verbal cue that you received an email).
- If your internet connectivity is not fantastic, sometimes turning off the camera for a bit will prevent some lagging.

PREPARE YOUR ATTENDEES

Getting your space ready and getting yourself ready for an online presentation are not your only preparatory tasks. You also need to get your audience ready by setting expectations for how they will communicate with the hosts or panelists. The more your audience knows what to expect, the more successful your presentation will be.

- Have a strategy for managing audience questions. Live questions from an online audience can easily get out of hand; however, you can let your audience know that questions should be entered in the Q&A format (Zoom webinars), through a raised hand, or in the chat box. You may want to assign a Zoom buddy to monitor the chat while you are presenting. This can be a colleague, or you might ask for a volunteer from the audience.
- The chat feature is wonderful in Zoom, but it can also lead to side conversations and well-intentioned but distracting comments. With Zoom you can allow attendees to chat privately with one another, publicly with the entire room, or just with the host. Consider blocking the ability of attendees to send messages to the whole room. These often add very little to the presentation and can be intrusive. As mentioned above, consider using the Q&A format if you have access to Zoom webinars.
- Remind attendees about their sound controls (i.e., Mute/Unmute). Online discussions in which more than a few people are participating at once are very difficult to control and should be avoided if possible.
- Set expectations for camera use. Cameras can be valuable tools for small seminars or classroom presentations, but they can also be distracting in a large meeting or session. Additionally, webcams take up bandwidth and slow the speed of the meeting.
- Finally, consider requiring registration so that attendees can receive relevant materials ahead of the class or meeting. Providing materials ahead of time not only will help attendees be prepared but also is a convenience for those who may want to print the documents and for those who may use assistive technologies to read the materials. This could include providing advance instruction for using the technology platform (e.g., Zoom).



COMPONENT 1:

COMPREHENSIVE TRAINING OF CENTER PROGRAM CHAMPIONS

The first step in implementing the TTTF Train the Trainer program is selection and comprehensive training of a center program champion(s). As stated previously, a program champion is a center employee, usually a clinician or manager, who is trained as a tobacco treatment specialist, and will lead the center's efforts in training employees on tobacco education. We recommend training 2-4 program champions per center, with a minimum of 2 per center. Training various employees to become program champions in your center will ensure that the necessary expertise to train employees on tobacco control is continuously embedded within your organization, given the high turnover of employees within behavioral health settings. Departing program champions can use this training program to ensure that they replace themselves within the organization. Program champions can be individuals who have or have not previously received training and certification as tobacco treatment specialists.

We have included a "Project Instrument Administration Timeline" for your convenience, to facilitate planning of the various steps involved in implementing this training program.

The first step in this program consists of a 5-hour comprehensive training of program champions in tobacco education, entitled "Master Tobacco Education Refresher" Training Slide Deck (Appendix B) (hereafter referred to as the "Master Training"), which, depending upon whether one has been previously trained or not, serves as either a refresher or a foundational course in tobacco education. As with our past work with behavioral health centers throughout Texas,

Project Instrument Administration Timeline

Administer "Program Champion Self-Assessment – Baseline Survey' for snapshot of champion selfefficacy before training begins

Utilize "Observer Ratings of Practice Instruction Feedback Form" to evaluate program champion's performance during practice sessions where they deliver mock

raining to employees at their center

Administer

"Program Champion Self-Assessment Pre-**Actual Training Survey** for snapshot of champion's selfefficacy at this point of program

Utilize "Observer Ratings of Actual Instruction Feedback Form" to evaluate program champion's performance during training delivered to employees

Administer "Employee Attendees" Post-Test & Ratings of Instruction Survey" after champion's employee training concludes

Send "Sample Certificate for Employee Attendees to program champion to distribute to those who attended their training

Fill out "Program **Champion Summary** Sheet" with analyzed data from employee attendees' pre + post test & evaluations,

Administer "Program Champion Self-Assessment Post Training & Ratings of **Curriculum & Training** Survey" for snapshot and send to champion of champion's selfefficacy at this point of

received

9

Fill out the "Sample Certificate for Program Champion" and send to champion to signify their successful completion of the training program program & evaluation of the training they

Project Instrument Administration Timeline (continued)

Hold focus group

Follow up with champions periodically using the "Post-**Implementation** Program Champion Survey" to collect data on number of trainings delivered & trainees to evaluate training program outcomes/

reach

Trainings delivered to program champions

Program champion "passes" the practice session and proceeds to organize the first training to be delivered to their fellow employees

trainings to trainers

Program champion delivers training to employees at their center

the content for this presentation is informed by recommendations for best practices in tobacco control, 15.16 the expertise of team members, and prior tobacco free workplace implementation work within substance use treatment centers and mental health settings, 21-23 and is a condensed version of the Certified Tobacco Treatment Specialist Training (CTTS). It consists of an intensive, 5-hour PowerPoint presentation that provides an overview of specialized knowledge pertaining to tobacco use and tobacco treatment strategies, focusing on:

- Tobacco Use among Vulnerable Groups (e.g. those who are: diagnosed with mental and/or substance use disorders, intellectual and developmental disabilities, vulnerably housed, members of a sexual minority and of lower socioeconomic status)
- Why People Use Tobacco: Marketing
- Why People Use Tobacco: Nicotine Addiction
- Benefits of Quitting
- Empirically Supported Treatments for Tobacco Dependence
- Tobacco Free Policies
- Behavioral Counseling and Interventions
- · Over-the-Counter Nicotine Replacement Therapy (NRT) and Prescription Medications
- Myths and Facts About Smoking among Those with Behavioral Health Conditions
- Motivational Interviewing Basics
- E-Cigarettes and ENDS
- Resources



As with all the materials in this *Implementation Guide*, the "Master Training" can be delivered live, in-person, or live via a web-based platform such as Zoom. Additional material specific to a treatment site (e.g., how to record information in consumer records or an electronic health system) and/or consumer population (e.g., pregnant smokers, youth who vape, opioid users), can be added to this presentation as needed. Please check our website, https://www.takingtexastobaccofree.com for presentations addressing smoking in special populations, i.e., among sexual minorities, people with opioid disorders, people experiencing homelessness, and those living in subsidized housing.

Upon completion of the "Master Training," program champions will have been trained on how tobacco use and environmental tobacco smoke affects the body; specifics about tobacco use among individuals with behavioral health conditions (i.e., mental health and substance use disorders); the most effective ways of treating tobacco use and dependence, including adoption of a tobacco free workplace policy; and how to assist others with maintaining compliance with the policy; and how to address barriers to treating tobacco use among those with behavioral health conditions. The "Master Training" contains 94 slides and serves as the basis from which shorter, 45, 60, or 90 minutes training presentations to be delivered to employees, can be developed.

This initial phase of training the program champions includes an optional, brief, 3-minute baseline assessment, the "Program Champion Self-Assessment-Baseline Survey" (Appendix C). This survey assesses the program champion's self-efficacy and experience with training and delivering educational curriculum to others. Program champions rate themselves on a 5-point scale ranging from "strongly disagree" to "strongly agree," on different characteristics, e.g. "I am a good public speaker," and "I currently have the capacity to deliver trainings in tobacco control." This same self-rating assessment is repeated both before and after the delivery of actual trainings to center employees. The purpose of this assessment throughout the training phase is to provide feedback to program champions on their training process and to build their confidence as trainers. It can also reveal opportunities for professional development that can be pursued/recommended.

Assessments/Tools:

- 1. TTTF General Video Conferencing Platform Training Instructions (Appendix A)
- 2. Master Tobacco Education Refresher Training Slide Deck (Appendix B)
- 3. Program Champion Self-Assessment-Baseline Survey (Appendix C)







COMPONENT 2:

DEVELOPMENT OF TAILORED EVIDENCE-BASED TOBACCO EDUCATION CURRICULUM

The second step, after being educated on the harms of tobacco use and how to effectively treat dependence, is to develop a tobacco education curriculum tailored to the needs and time preferences of the individual center. The "Master Training" slides serve as the basis for the development of the 3 different types of center-led trainings, New Employee, Annual, and In-service Training events. As every center is unique, the length of each of these training events is decided by the individual center. We have developed the "90-minute Employee Training Slides"(Appendix D) consisting of 30 slides, condensed from the "Master Training," that each of the 3 local mental health authorities that piloted this training program adopted in their centers for their Annual Employee Training. These training slides include presenter notes to facilitate learning. However, we encourage trainers to put the slide notes into terms they are comfortable with, delivering the presentation in their own words, rather than struggling to use terms that may be unfamiliar to them. Additionally, many of our trainers have used personal stories to explain some of the training material with great success. Sharing your own experience about a topic being covered in a slide with attendees is the best way to make it real and engage their interest.

We recommend that the "90-minute Employee Training Slides" also be used for New Employee Training, whereas shorter presentation can be developed for the In-service Trainings. Through our <u>YouTube channel</u> on our Train the Trainer webpage, we also provide a video that models what a 90-minute tobacco dependence and education training video may look like. In this training video, viewers will identify the impact smoking and tobacco use has on people living with a mental illness and/or a substance use disorder. The goal of this phase of the training is to teach program champions presentation skills and teaching strategies in delivering the content of the deck as effectively as possible.

Certain slides in the "Master Training" are marked in the upper right-hand corner by a red star * and/or a capital green T. The star indicates that the slide is considered essential information that needs to be included in the basic employee training. While we recommend that trainers use the "90-minute Employee Training Slides," we are aware that your center may edit the presentation to accommodate shorter time frames. The red star * is meant to assist you in determining which slides are most essential. The green, upper-case T, identifies the slide as answering a test-question on the TTTF-developed pre- and post-training knowledge test. If your center intends to utilize the pre- and post-training tests (described below), all the slides marked with an upper-case, green T will need to be included in your employee training presentation, or you will need to modify the pre- and post-training tests.

Assessments/Tools:

1. 90-minute Employee Training Slide Deck (Appendix D)





COMPONENT 3:

PRACTICE TRAINING SESSIONS: TRAINING AND ASSESSMENT OF PROGRAM CHAMPION(S) ON DELIVERY OF TOBACCO EDUCATION CURRICULUM

Once your center program champion(s) has downloaded, and made any necessary adjustments, to the <u>90-minute</u> <u>employee presentation</u>, they will start the process of training to deliver the tobacco training to center employees. This process consists of 4 steps:

- 1. Program champion(s) study the Employee Training Presentation that they intend to present, to thoroughly familiarize themselves with the information.
- 2. To help prepare for delivering the training, we have written up suggested "Presentation/Teaching Tips" (Appendix E), to assist program champions.
- 3. Program champion(s) schedule at least 2 practice sessions in which they deliver a "mock training" of the Employee Training Presentation to at least 2 center "training observers/assessors." Training observers/assessors are other center employees, e.g., peers or other program champions who will assess the program champion on their delivery and mastery of training material.
- 4. Training observers will provide program champions with verbal and written feedback, using an assessment tool developed by TTTF, the "Observer Rating of Practice Instruction Feedback Form" (Appendix F). At the end of each practice session:
 - a. feedback is summarized and delivered verbally to the program champion
 - b. the written observer feedback forms are given to the program champion for a more detailed evaluation and recommendations for improvement
- 5. Program champions are scheduled for additional practice sessions if one or both of the following conditions are met:
 - a. One or both observers give program champion(s) a rating of 3 or less in the Overall ratings section of the "Observer Rating of Practice Instruction Feedback Form," which measures the following 2 items on a scale of 1-5, where 1 = Poor and 5 = Excellent:
 - 1. The delivery of the training curriculum by the trainer to setting stakeholders
 - 2. The effectiveness of the trainer as a teacher
 - b. The program champion requests additional practice sessions









*NOTE: If neither of the conditions are met and both observers agree that the program champion earned a true 4-5 on the overall ratings section of the feedback form, then program champion can proceed to Step 6 below. Otherwise, program champions will continue to schedule additional practice sessions until they receive a 4-5 overall ratings on the observer feedback form.

6. The training observers determine that the program champions have developed enough skill and confidence in delivering the training material effectively to move on to the next step and communicate to the program champions that they are ready to progress to the next step—delivering actual trainings to center employees.

If your center is training more than one program champion, we recommend having other program champions attend these practice sessions of their colleagues, optimally as assessors, as observing other program champions during training is a good way to gain valuable training experience and expertise for other champions-in-training, and to support them in their efforts. Our pilot program partners reported that training as a group, where program champions attended each other's trainings, was extremely helpful for them, providing an invaluable learning experience.

Assessments/Tools:

- 1. Presentation/Teaching Tips (Appendix E)
- 2. Observer Rating of Practice Instruction Feedback Form (Appendix F)



COMPONENT 4:

DELIVERY AND ASSESSMENT OF ACTUAL INSTRUCTION TO CENTER EMPLOYEES

Program champions are now ready to deliver tobacco education trainings to center employees. Program Champions begin scheduling procedures to deliver the curriculum to employees at their respective center. Each champion is scheduled to deliver the curriculum to 10-15 employees for ideally 2 trainings—the champion may need to coordinate with administrative/managerial leaders to send out the appropriate information and invitations to employees at their center.

The delivery and assessment of actual instruction to center employees consists of the following steps, whether the training is being conducted in-person or virtually. The only difference between the in-person and virtual trainings is that for the in-person trainings, the program champions and observers/assessors have the option of printing out and using hard copies of the different assessment instruments.

Prior to conducting the actual trainings:

- 1. Starting a week before the scheduled tobacco education training, registered attendees will be asked by the program champion(s) or their designee to complete an anonymous "Employee Attendees' Tobacco Education Training Pre-Test" (Appendix G) before the training begins. This provides a knowledge measure pre-training that can be compared with a post-training knowledge assessment. The program champion should ensure all employees are signed in, so they have a record of attendance, and their correct name for filling out the "Sample Certificate for Employee Attendees" (Appendix H) at the conclusion of the training.
- 2. A week prior to the actual training, registered attendees are emailed a "Training Package," that includes a copy of the PowerPoint slides, so that they can take notes, should they so desire, as well as the 2 handouts, one on "Drug Interactions with Tobacco Smoke," (<u>Appendix I</u>) and a "Pharmacologic Product Guide," (<u>Appendix I</u>), that details FDA-approved medications to treat tobacco use and dependence. Program champions may also wish to send out instructions for accessing the presentation platform (e.g., Zoom) as well to maximize their preparation.
- 3. During the week before the program champion is scheduled to deliver their first actual employee training, they will be administered the "Program Champion Self-Assessment Pre-Actual Training Delivery Survey" (Appendix K) online to assess their self-efficacy related to training others on the educational curriculum, specifically in relation to where they stood when surveyed in the beginning of the program.
- 4. The program champion will enlist the assistance of 2 observers/assessors to observe them delivering the employee training. The 2 observers will be assessing their performance and efficacy in the delivery of the curriculum using the "Observer Rating of Actual Instruction Feedback Form" (Appendix L). Ideally, both observers would rate the program champion a 4-5 (Very Good or Excellent) on the Overall Ratings section of the form, which is the same measurement as the "Observer Rating of Practice Instruction Feedback Form" (Appendix F).
- 5. At the end of the employee training, feedback should be summarized and delivered verbally to the program champion, and the observer feedback forms should be given as a follow up for a more detailed evaluation.

At the conclusion of the delivery of the actual trainings:

6. The program champion will send out a link to the "Employee Attendees' Post Test" (<u>Appendix M</u>) and "Employee Attendee Ratings of Training Instruction," (<u>Appendix N</u>), using SurveyMonkey or another free survey software platform.

Sustainable Education/Training Program Implementaion Guide | 23

Alternatively, for in person trainings, these materials can be printed out and physically distributed.

- ***NOTE: Steps 1-6 above should be repeated for every employee training the program champion delivers as part of the training program (ideally twice).
- 7. Program champions will fill out and email (or print and distribute) individual "Sample Certificate for Employee Attendees" (Appendix H) for the employee's participation in their training.
- 8. Once the program champions have successfully delivered 2 or more actual trainings to employees and have received a rating of 4-5 (Very Good or Excellent) from their observers/assessors, they will complete the "Program Champion Self-Assessment Post-Training Delivery & Trainer Ratings of TTTF-Provided Curriculum and Training" (Appendix O).
- 9. Center employees can analyze the data on knowledge gain as well as employee attendee ratings of their training and their performance using the "Employee Attendees' Tobacco Education Training Pre-Test" (Appendix G) (administered in Step 1 above), and the "Employee Attendees' Post Test & Ratings of Instruction Survey" (Appendix M) (administered in Step 6 above).
- 10. The data from "Employee Attendees' Tobacco Education Training Pre-Test" (Appendix G) and the "Employee Attendees' Post Test" (Appendix M) & "Employee Ratings of Training Instruction" (Appendix N) should be compiled and entered into the "Program Champion Summary Sheet" (Appendix P), and be delivered to the presenting program champions upon completion. Appropriate attention should be given to ensure comments provided to the champions on this document are not unnecessarily derogatory or potentially identifiable in the case of very small employee trainings. It is best to identify major themes from employee comments and select 1-2 representative ones for inclusion on the summary sheet. The person compiling this information for the program champions might also make corresponding recommendations for how to address any critical feedback in future trainings on this summary sheet. It is important to be encouraging and helpful to the program champions in this regard.
- 11. A "Sample Certificate for Program Champion" (<u>Appendix Q</u>) should also be tailored for the program champion(s) and sent to them for their participation and successful completion of the training program.
- 12. Additionally, an optional "Program Champion Post-Implementation Interview Guide" (<u>Appendix R</u>) is included for a more in-depth evaluation of the training program.

Assessments/Tools:

- 1. Employee Attendees' Tobacco Education Training Pre-Test (Appendix G)
- 2. Sample Certificate for Employee Attendees (Appendix H)
- 3. Drug Interactions with Tobacco Smoke (Appendix I) Pharmacologic Guide (Appendix I)
- 4. Program Champion Self-Assessment Pre-Actual Training Delivery Survey (Appendix K)
- 5. Observer Rating of Actual Instruction Feedback Form (Appendix L)
- 6. Employee Attendees' Post Test (Appendix M) and Employee Ratings of Training Instruction (Appendix N)
- 7. Program Champion Self-Assessment Post-Training Delivery & Trainer Ratings of TTTF-Provided Curriculum and Training (<u>Appendix O</u>)
- 8. Program Champion Summary Sheet (Appendix P)
- 9. Sample Certificate for Program Champion (Appendix Q)
- 10. Program Champion Post-Implementation Interview Guide (Appendix R) (Optional)





COMPONENT 5:

INTEGRATION OF REGULAR TOBACCO EDUCATION
INTO NEW EMPLOYEE TRAININGS, ANNUAL
EMPLOYEE TRAININGS, AND IN-SERVICE TRAININGS

Once the program champions have successfully completed their training in becoming tobacco educators, they will work with their departmental and center partners to integrate regular tobacco education into New Employee Trainings, Annual Employee Trainings, and In-service Trainings. Interdepartmental cooperation and planning are necessary to develop a sustained training program. Program managers are ultimately responsible for the education of their employees and cooperating with program champions to ensure that employees' work schedules can accommodate periodic tobacco training events. It is essential that in-house expertise regarding tobacco treatment is consistently maintained within the center to effectively address tobacco dependence.

ONGOING TRAINING

Behavioral health centers historically have a high employee turnover rate; keeping knowledge current and appreciation for the purpose behind the tobacco free workplace is essential to its sustainability. Therefore, it is important to focus on adequately training all new employees and this can be accomplished by embedding this training within New Employee Orientation, Annual Employee Training, and In-service Trainings. New employees should also receive training on addressing people who choose to break the tobacco free workplace policy. Policy violation/treatment resource cards to hand out, role playing how to approach violators in the workplace, and different examples of scripts for education about the tobacco free workplace policy (available under Implementation Resources, Tobacco free campus policies, on our website) should be provided to new employees during this training. These resources are available on our website, https://www.takingtexastobaccofree.com. New employees can also shadow current employees to become familiar with the processes and procedures.

ONGOING TRAINING: MAINTAINING TOBACCO TREATMENT COMPETENCY

It is essential that as many clinicians as possible are provided a high level of tobacco treatment training and that the training is ongoing and sustainable. A significant barrier preventing clinicians from addressing tobacco use is a lack of training, knowledge, and skills to adequately assist a person with a quit attempt. A robust training program will provide the foundation for competent and highly skilled clinicians and ensure that all employees have a consistent level of knowledge. The more employees who have a higher level of tobacco treatment training, the more likely consumers are going to be screened, referred for treatment, provided resources for quitting, and followed up.



Program champions should incorporate ongoing tobacco treatment training as refresher courses and webinars for current clinicians, provide periodic advanced level training (e.g., Treating Tobacco Dependence in Mental Health Settings —Dr. Jill Williams) for nurses and clinicians, and commit to either training other employees in treating tobacco dependence using the "Master Training," or alternately, sending employees to become Certified Tobacco Treatment Specialists (CTTS). Ideally, before providing tobacco treatment services to a consumer, a training program should be developed for credentialing clinicians. Additionally, if program champions are moving on to other organizations, they can plan to replace themselves by training other employees, using this training program, to become program champions. Without a consistent training program, untrained employees are less likely to talk with consumers about their tobacco use or may provide incorrect and/or potentially harmful information to a consumer.

Centers should encourage clinicians to take advantage of high-quality free online resources and webinars. Some examples include:

- Smoking Cessation Leadership Center: (http://smokingcessationleadership.ucsf.edu/webinars)
- National Behavioral Health Network For Tobacco & Cancer Control: (https://www.bhthechange.org)

Additionally, there are many CTTS programs available across the country. For a full list of CTTS program, visit https://www.attud.org/. Below is a list of some programs we are familiar with:

- MD Anderson Certified Tobacco Treatment Training Program:
 https://www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/certified-tobacco-treatment-training-program-.html
- Mayo Clinic Nicotine Dependence Education Program:

 http://www.mayo.edu/research/centers-programs/nicotine-dependence-center/education-program/overview
- University of Massachusetts Medical School: http://www.umassmed.edu/tobacco
- Rutgers University Tobacco Dependence Program: http://www.tobaccoprogram.org
- Florida State University College of Medicine:
 http://med.fsu.edu/index.cfm?page=ahec.tobaccoTreatment
- University of Mississippi Medical Center:

 Act Center for Tobacco Treatment, Education and Research:

 http://www.act2quit.org/education
- University of Colorado School of Medicine: RMTTS-C Program: https://www.bhwellness.org/programs/rmtts





TOBACCO TREATMENT MEDICATION AVAILABILITY

Breaking the dependence on tobacco is very difficult; only 3–5% of people are able to quit without any assistance.²⁴ It is important that processes and procedures be developed to provide convenient and inexpensive access to tobacco treatment medications. The availability of the medications will likely reduce anxiety and fear among consumers (and employees), provide a valuable incentive to make a quit attempt, and show that the organization wants to support tobacco users to quit rather than punish them for using tobacco.

Many behavioral health centers are concerned about how to pay for tobacco treatment medications for consumers. Many consumers receiving services do not have private insurance, and if they do, nicotine replacement therapy (NRT) and other medications may not be covered.

One way to offset the cost of providing medications is to utilize the Patient Assistant Program (PAP). PAP provides free or very low-cost medications to people who meet financial need requirements. Varenicline (Chantix) and buproprion (Wellbutrin/Zyban) are typically available through PAP formulary.

Centers can also bill for reimbursement for tobacco treatment services. Revenue generated from the billing will likely not cover the costs for the service, but it could be used to defer some of the cost to purchase NRT or other medications.

To further reduce the cost burden of purchasing NRT, non-profit organizations may be able to access NicoDerm CQ™ patches and Nicorette™ gum and mini lozenges manufactured by GlaxoSmithKline Client Healthcare through their NRT - Direct Purchase Program (DPP). DPP provides NRT to organizations at a significantly discounted rate. For more information on the NRT DPP Program, please contact:

Jim Karl

U.S. Expert Sales: Regional Account Manager, Healthcare Solutions GlaxoSmithKline Client Healthcare

184 Liberty Corner Road, Warren, New Jersey, 07059, United States

Email: james.f.karl@gsk.com

Cell: 618-558-7459

Some other options to cover the cost for tobacco treatment medications include collaborating with the center's development/fund raising specialists to solicit funds. Members of a work group can also explore local or regional community foundations, hospital foundations, community donations, or local, regional, or state grants. CVS Pharmacy has community grants available to organizations who provide tobacco treatment services. Visit their Community Grants website to learn more: https://cvshealth.com/social-responsibility/our-giving/corporate-giving/community-grants

Tobacco treatment medications should also be made available to all employees. Your center will want to review their insurance coverage and determine:

- What tobacco treatment medications are covered?
- How long can an employee access the medication?
- Any applicable co-pays and/or pre-authorization requirements, and
- Whether cessation groups and/or individual counseling charges are covered.

Coverage benefits should be communicated to all employees in advance of the tobacco free workplace policy implementation and employees should be reminded of the benefits on a regular basis before and after the tobacco free workplace policy becomes effective. Implementing organizational screensavers with this information and/or including it on within-organization media may be helpful to enhance communication.

The Affordable Care Act has mandated that compliant insurance carriers include tobacco cessation services among their coverage. If your organization's insurance plan has limited or no coverage for tobacco treatment services, the Human Resources department should inquire about implementing this required benefit. If medications are not covered under the insurance plan, it becomes critical for the organization to provide tobacco treatment medications to interested employees. For instance, the organization should consider adding tobacco treatment medication expenses as a line item in the general budget. For example, an organization serving approximately 20,000 consumers that employs approximately 1,000 employees should expect to budget between \$50,000 and \$80,000 annually for NRT. Please contact our GlaxoKlineSmith representative, Jim Karl, email: james.f.karl@gsk.com (additional information included previously), about receiving a discount on NRT products and calculating the estimated cost for your center's needs.











FREQUENTLY ASKED QUESTIONS

The following are some of the more commonly asked questions or concerns of behavioral health centers implementing the TTTF program:

Can this training program be implemented during COVID-19?

Yes. The entire TTTF Education/Training Program has been designed to be implemented and delivered either online using a video-conferencing platform such as Zoom, or inperson. Components 1–5 can be delivered online along with the different assessment and other helpful tools.

Is it better to train in-person or live online?

Optimally, we would recommend training in-person, whenever feasible, as participants are generally more comfortable, attentive, and easily engaged during a live, in-person training rather than online. However, we recognize that in-person training may not always be feasible or safe and have made this training program available for live, online delivery. Alternatively, a hybrid approach using in-person and live, online training may appeal to your center employees.

Can this training be delivered using a previously recorded training presentation?

While live delivery of this training is recommended, whether in-person or live online, that may not always be feasible. We have recorded a 90-minute Employee Education and Training Video, both as a model for trainers on how to deliver the training as well as an alternative when a live training is not feasible, that can be accessed via our webpage at www.takingtexastobaccofree.com, under our Train the Trainer program or directly on YouTube.

What technology is required for training remotely/ online?

General technology prerequisites/requirements include:

- Computer with inbuilt or external microphone & webcam
- Zoom software (online download)

• Microsoft Teams (integrated into Microsoft 365 platform)

In <u>Appendix A</u>—"TTTF General Video Conferencing Platform Training Instructions," we provide detailed instructions on how to conduct trainings using Zoom and Microsoft Teams. We recommend that you practice delivering the online training various times, particularly if you are not very familiar with the technology that you are using. Practicing using the technology will ensure that your presentation is technologically trouble-free so you can focus of on delivering the content to your colleagues.

What if I encounter technological problems?

We recommend that you consult your center's IT specialists prior to commencing any online trainings to ensure that your equipment (computer, microphone, and webcam) and software programs are functioning correctly prior to conducting any portion of the training online. It is important that the technological aspects of the training function well so as not to distract from, but instead support a smooth delivery of the training.

Employees at my center are very busy, scheduling a 90-minute tobacco training will be challenging. How long should the training presentations be?

We understand that behavioral health centers are busy places and employees have tight schedules. The "90-minute Employee Training Slides" <u>Appendix D</u> developed for this training serve as the basis from which trainers can draw to tailor a presentation according to the needs of their specific center. While our training partners have generally preferred a 90-minute presentation for the basic employee training, a 60- or 45-minute presentation could also be effective. Alternately, trainers may choose to break the basic, general tobacco education training into shorter segments delivered

consecutively. Or, trainers may choose to periodically deliver a shorter presentation, focused on a particular aspect of tobacco control, e.g., FDA-approved medications such as nicotine replacement therapy and prescription medications, or behavioral interventions for treating tobacco dependence, as booster educational

sessions. These shorter segments might be particularly suited to periodic, In-service Trainings.

How you choose to schedule the delivery of tobacco education depends upon your center's particular needs and characteristics. However, adequately training clinicians on how to treat tobacco addiction is the cornerstone to effective tobacco control. As such, we encourage your center to find a way of delivering adequate tobacco education to your employees to reduce tobacco consumption and contribute to improving the health of your employees, consumers, and center visitors. Should you need additional assistance with implementing this training program, please contact us at: https://www.takingtexastobaccofree.com.

Do I have to deliver the tobacco training word-for-word, exactly as it is written in the slides?

No. We encourage presenters to "translate" or adapt the slide notes into their own language. The notes are provided to facilitate learning and highlight important information on the slides. Adapting and delivering the presentation in your own words will increase your comfort level with the material and attendee engagement. We also encourage you to make the presentation your own through including real-life experiences and stories on the material that is being presented. Sharing your own experience on a certain topic is a wonderful way of enlivening the presentation and engaging your audience with the material. Obviously, confidential, or identifiable information about current or former consumers should not be shared; many of our program champions find examples from their own personal lives to present.

Where can I get additional program materials, such as educational brochures on tobacco control?

On our website we provide various educational and dissemination materials for free. Please visit https://www.takingtexastobaccofree.com, under Tools, please select Download Center, where you will find various informational,

or rack, cards, posters, quit cards and our One-Page Taking Texas Tobacco Free brochure available for download for free in English, Spanish, Vietnamese, Chinese, Japanese, and Farsi.

What happens if our tobacco education program champions leave our organization?

Behavioral health centers often experience high employee turnover. This is one of the primary reasons that we encourage training 2-4 employees as tobacco education program champions. If program champions are moving on to other organizations, they can plan to replace themselves by training other employees, using this training program, to become program champions. Without a consistent training program, untrained employees are less likely to talk with consumers about their tobacco use or may provide incorrect and/or potentially harmful information to a consumer.

How can I stay informed about current research and policy recommendations on e-cigarettes, vaping, JUUL, etc.?

The tobacco industry is constantly developing new electronic nicotine delivery systems (ENDS), many targeting youth and teens, that have been shown to be particularly harmful to developing youth. To stay abreast of the current research on the harms of these products and recommendations or guidelines regarding their use, please check out the following websites:

- American Cancer Society Position Statement on Electronic Cigarettes. November 2019 https://www.can-cer.org/healthy/stay-away-from-tobacco/e-cigarette-position-statement.html
- Center for Disease Control (CDC) Smoking and Tobacco
 Use: Electronic Cigarettes: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/index.htm
- Our website, Taking Texas Tobacco Free: https://www.takingtexastobaccofree.com
- Visit http://txsaywhat.com or the Campaign for Tobacco free Kids: https://www.tobaccofreekids.org and the Truth Initiative https://www.thetruth.com to get involved in campaigns to raise awareness of the dangers of nicotine addiction and e-cigarettes to youth.



BIBLIOGRAPHY

- 1. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA. 2000;284(20):2606-2610. doi:10.1001/jama.284.20.2606 (https://jamanetwork.com/journals/jama/fullarticle/193305) [BACK]
- 2. Annamalai A, Singh N, O'Malley SS. Smoking Use and Cessation Among People with Serious Mental Illness. Yale J Biol Med. 2015;88(3):271-277. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553647/) [BACK]
- 3. McGinty EE, Zhang Y, Guallar E, et al. Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv. 2012;63(7):714-717. doi:10.1176/appi.ps.201100169 (https://ps.psychiatryonline.org/doi/full/10.1176/appi.ps.201100169) [BACK]
- 4. Howard LM, Barley EA, Davies E, et al. Cancer diagnosis in people with severe mental illness: practical and ethical issues. Lancet Oncol. 2010;11(8):797-804. doi:10.1016/S1470-2045(10)70085-1 (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70085-1/fulltext)
- 5. Callaghan RC, Veldhuizen S, Jeysingh T, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res. 2014;48(1):102-110. doi:10.1016/j.jpsychires.2013.09.014 (https://www.sciencedirect.com/science/article/abs/pii/S0022395613003063?via%3Dihub)
- 6. Maddock J, Hayes D, St John TL, Rajan R, Sheehan WP. Public Health Hotline: Morbidity and Mortality in People with Severe and Persistent Mental Illness in Hawai'i. Hawai'i J Med Public Heal. 2012;71(11):326-328. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497918/)
- 7. Steinberg ML, Williams JM, Li Y. Poor Mental Health and Reduced Decline in Smoking Prevalence. Am J Prev Med. 2015;49(3):362-369. doi:10.1016/j.amepre.2015.01.016 (https://www.ajpmonline.org/article/S0749-3797(15)00036-7/full-text) [BACK]
- 8. Jasek JP, Williams JM, Mandel-Ricci J, Johns M. Trends in smoking among adults with serious psychological distress during comprehensive tobacco control in New York City, 2003-2012. Tob Control. 2015;24(6):622-623. doi:10.1136/tobaccocontrol-2014-052024 (https://tobaccocontrol.bmi.com/content/24/6/622)
- 9. Lawrence D, Williams JM. Trends in Smoking Rates by Level of Psychological Distress-Time Series Analysis of US National Health Interview Survey Data 1997-2014. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2016;18(6):1463-1470. doi:10.1093/ntr/ntv272 (https://academic.oup.com/ntr/article-abstract/18/6/1463/1752937?redirectedFrom=fulltext&login=false)
- 10. Anderson P, Hughes JR. Policy interventions to reduce the harm from smoking. Addiction. 2000;95 Suppl 1:S9-11. doi:10.1080/09652140032017 (https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1360-0443.95.151.6.x) [BACK]
- 11. Ong MK, Glantz SA. Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. Am J Public Health. 2005;95(6):969-975. doi:10.2105/AJPH.2004.040667 (https://pubmed.ncbi.nlm.nih.gov/15914818/)
- 12. Hopkins DP, Razi S, Leeks KD, Priya Kalra G, Chattopadhyay SK, Soler RE. Smokefree policies to reduce tobacco use. A systematic review. Am J Prev Med. 2010;38(2 Suppl):S275-89. doi:10.1016/j.amepre.2009.10.029 (https://www.ajpmonline.org/article/S0749-3797(09)00751-X/fulltext) [BACK]

- Sustainable Education/Training Program Implementaion Guide | 31
- 13. Brownson RC, Hopkins DP, Wakefield MA. Effects of smoking restrictions in the workplace. Annu Rev Public Health. 2002;23:333-348. doi:10.1146/annurev.publhealth.23.100901.140551 (https://www.annualreviews.org/doi/10.1146/annurev.publhealth.23.100901.140551) [BACK]
- 14. Mudarri D. The Costs and Benefits of Smoking Restrictions: An Assessment of the Smoke-Free Environment Act of 1993 (HR 3434): Executive Summary. Indoor Air Division 66o7J, Office of Radiation and Indoor Air, US Environmental Protection Agency; 1994. (https://nepis.epa.gov/Exe/ZyNET.exe/100045VS.TXT?ZyActionD=ZyDocument&Client=EPA&Index=1991+Thru+1994&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&Q-FieldYear=&QFieldDay=&IntQFieldOp=o&ExtQFieldOp=o&XmlQuery=&File=D%3A%5Czyfiles%5CIndex%20Data%5C91thru94%5CTxt%5C00000011%5C100045VS.txt&User=ANONYMOUS&Password=anonymous&Sort-Method=h%7C-&MaximumDocuments=1&FuzzyDegree=o&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=hp-fr&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=1&ZyEntry=1&-SeekPage=x&ZyPURL)
- 15. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs—2014. Atlanta, GA. Available at: https://www.cdc.gov/tobacco/stateandcommunity/best_practices/pdfs/2014/comprehensive.pdf. [BACK]
- 16. Fiore M, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Public Health Service; 2008. Available at: https://biznet.ct.gov/rfpdoc/dph/results/2009-0916.pdf
- 17. U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General—Executive Summary. Atlanta, GA; 2016. (https://e-cigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf) [BACK]
- 18. Walsh RA, Bowman JA, Tzelepis F, Lecathelinais C. Smoking cessation interventions in Australian drug treatment agencies: a national survey of attitudes and practices. Drug Alcohol Rev. 2005;24(3):235-244. doi:10.1080/09595230500170282 (https://onlinelibrary.wiley.com/doi/abs/10.1080/09595230500170282)
- 19. Sheals K, Tombor I, McNeill A, Shahab L. A mixed-method systematic review and meta-analysis of mental health professionals' attitudes toward smoking and smoking cessation among people with mental illnesses. Addiction. 2016;111(9):1536-1553. doi:10.1111/add.13387 (https://onlinelibrary.wiley.com/doi/10.1111/add.13387)
- 20. Graydon MM, Corno CM, Schacht RL, et al. A statewide initiative to train behavioral health providers in smoking cessation. Transl Behav Med. 2018;8(6):855-866. doi:10.1093/tbm/iby086 (https://academic.oup.com/tbm/article/8/6/855/5092897?login=false)
- 21. Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. Am J Drug Alcohol Abuse. 2017;43(2):215-225. doi:10.1080/00952990.2016.1183019 [BACK]
- 22. Lawn S, Campion J. Achieving smoke-free mental health services: lessons from the past decade of implementation research. Int J Environ Res Public Health. 2013;10(9):4224-4244. doi:10.3390/ijerph10094224
- 23. McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review. Addict Behav. 2017;65:161-170. doi:10.1016/j.addbeh.2016.10.012 (https://www.tandfon-line.com/doi/abs/10.1080/00952990.2016.1183019?journalCode=iada20)
- 24. Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA. 2012;308(15):1573-1580. doi:10.1001/jama.2012.13043 (https://jamanetwork.com/journals/jama/article-abstract/1383221) [BACK]



APPENDIX A

TTTF GENERAL VIDEO CONFERENCING PLATFORM TRAINING INSTRUCTIONS

TTTF GENERAL VIDEO CONFERENCING PLATFORM TRAINING INSTRUCTIONS

TTTF has used Zoom and Microsoft Teams video conferencing platforms for the virtual tobacco dependence treatment and education trainings. Below are information and instructions for the use of each video conferencing platform, followed by some helpful tips.

GENERAL PREREQUISITES/REQUIREMENTS:

- Computer with inbuilt or external microphone & webcam
- Zoom software (online download—instructions below)
- Microsoft Teams (integrated into Microsoft 365 platform)

ZOOM DOWNLOAD INSTRUCTIONS FOR TRAINING ATTENDEES

- 1. Enter the URL for the meeting into any browser (Google Chrome, Internet Explorer, etc.) DO NOT SHARE THE URL LINK WITH ANYONE ELSE.
- 2. If a dialog box opens, click "ok" to open the meeting in Zoom. Otherwise, you can download Zoom, by clicking the download & run zoom button/text on the webpage for the URL.
- 3. Once the installer downloads, click on it to complete the download for Zoom. This is possible on Windows, iOS, and Android operating systems.
 - a. If you are downloading and using Zoom for the first time, you will have to enter the URL for the meeting once again to access the meeting.
- 4. Once Zoom opens, you may or may not be asked for a password. If you are asked for a password, you can find the password in the meeting invite or email and upon entering the password, you will also be prompted to type in your name. Type in your name as you want to be known to others.
- 5. Next, you will be asked to join the conference. Depending on your device, click either "join by computer" or "join by telephone."
- 6. You will be automatically muted; however, if you are not, please do so by clicking on the button resembling a microphone.

MICROSOFT TEAMS INSTRUCTIONS FOR TRAINING ATTENDEES

- 1. Ensure that Microsoft Teams is included in your Microsoft suite. You may need to contact your IT/MIS department to determine whether your Microsoft suite includes Teams.
- 2. Enter the URL for the meeting into any browser (Google Chrome, Internet Explorer, etc.) or click on the link included in a meeting invite. DO NOT SHARE THE URL LINK WITH ANYONE ELSE.
- 3. You should not need to download any programs and the video conference should be begin after clicking on the provided link. You may need to "ask" to join the meeting, depending on when you join, and the settings established by the trainer.

APPENDIX A

(CONTINUED)

ADDITIONAL TECHNOLOGY TIPS:

- For both Zoom and Teams, attendees can use the CHAT function to make general comments or ask questions about technical issues. The CHAT feature is located in different areas for each platform (Zoom located on bottom task bar; Teams locate in upper right corner)
- Zoom helpful hint: If you are currently viewing a presentation in full screen mode but need to view the presenter's screen for a live demonstration (e.g., to see what a nicotine patch looks like), press "Esc" to exit full screen mode.
- Your video may be off automatically; however, if you are participating in group activities or you desire to have your video on (or if it is requested/required by the presenter), you will be able to turn on your video by clicking on the video camera icon on the bottom ribbon on your screen.
- Try not to have additional applications running at the same time as a video conferencing call. Also, ensure optimal internet connection for undisturbed audio and video.
- To ensure that all attendees can hear the presentation, please mute your microphone when you join and after you make a comment or ask a question.
- Zoom helpful hint #2: Attendees may wish to have a phone handy, in case their audio is not working, so they can call in. In this case, the attendee should mute themselves on 1 device.

TIPS FOR PRESENTERS:

- Practice using the video conference platform with colleagues several times before your presentation. Do not assume you will be able to "figure it out" on the day of the training.
- Log on 15–30 minutes early to ensure that everything is working and to allow you time to troubleshoot any problems you may experience. You may also need to "accept" people into your presentation depending on the security settings. You want to be there first so people are not waiting to join.
- Ensure that you have access to the training materials/PowerPoint and your notes on your computer or network drive. Have the training backed up on a flash drive in the event that you cannot access a network drive, or you experience problems with your computer and need to use a back-up computer. Print your notes in the event that you cannot pull the notes up with your training. With Teams, you can also use presenter mode in PowerPoint to be able to view the slide notes while delivering the presentation.
- For Zoom while presenting in a Webinar mode, for attendees to ask a question to the presenters, use the **Q/A function** on the bottom ribbon of the screen.
- Zoom helpful hint #3: For Zoom, if you wish to play a video, be sure to click on "Enable Sound" on the Share screen.

 If you do not do this, your video will play but the attendees will not be able to hear it.

APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER










Tobacco Use among Vulnerable Groups














MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)














Why People Use Tobacco: Marketing





APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)












R.J. Reynolds executive's reply when asked why he didn't smoke according to Dave Goerlitz, lead Winston model for seven years for R.J. Reynolds.] Giovanni, J, "Come to Cancer Country; USA; Focus," The Times of London, August 2, 1992.



Why People Use Tobacco: Nicotine Addiction



addictive:

 Presence of ammonia or ammonia compounds => increase the speed in which nicotine is delivered to the



Taking Texas Tobacco Free website: https://www.takingtexastobaccofree.com/addiction-videos

Quitting, Brain chemistry-Mayo Clinic: https://www.youtube.com/watch?v=5ewwzazHfq4


Mayo Clinic: https://www.youtube.com/watch?v=IpWMgPHn0Lo

Understanding Nicotine Addiction

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)




















APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)






















MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)




















APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)






















MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)

Example of Procedures at a LMHA: Gulf Coast 1. Each time an individual is seen by a provider the individual will be assessed for current tobacco use, frequency of tobacco usage, and desire to quit. 2. Nursing staff or other designated staff will complete initial tobacco use screening and cessation intervention utilizing the Flow Sheet and record in SmartCare/EHR. 3. Designated staff will provide individuals with continual ongoing assessment for desire to quit as needed, both in and outside of the clinic setting. 4. If individual indicates they are currently using tobacco then Tobacco Use Intervention must be completed and documented in SmartCare/EHR. 5. Designated staff will provide clients with a quit card and, if appropriate, information on the text message program (https://smokefree.gov)












Motivational Interviewing Basics






APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)







Recognize and Reinforce "Change Talk" and Readiness




Tools to get Change Talk





MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)









E-cigarettes and Electronic Nicotine Delivery Systems





Use of ENDS should be discouraged and not be used as a first line cessation method



APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)












Additional Resources







TTTF Website

APPENDIX B

MASTER TOBACCO EDUCATION REFRESHER (CONTINUED)









"When we started the initiative, it was amazing how wrong we were as mental health professionals because many of us have been in this field a long time and we always assumed that our clients didn't want to stop smoking because they couldn't or if they did their symptoms would get worse. We never even thought to ask them and once we realized our clients [were open to quitting] we really just asked them and they did not want to continue smoking. And once we became an instrument to help them, a lot of the clients were quite successful."

-Debra Shedrick, Program Manager Spindletop Center

....



Sustainable Education/Training Program Implementaion Guide | 47

APPENDIX C

PROGRAM CHAMPION SELF-ASSESSMENT—BASELINE SURVEY

Program Champion Self-Assessment BASELINE

What is your name? _		
What center do you v	vork for?	
For how long have yo	ou been training/	educating others (in years/months)?
Total =	_ years and	months.
For how long have you years/months)?	ou been training/	educating others in tobacco control specifically (in
Total =	years and	months.

Please rate your level of agreement with the following items:


	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
I am a good public speaker.	1	2	3	4	5	N/A
I currently have the capacity to deliver trainings in tobacco control.	1	2	3	4	5	N/A
I have observed others conducting tobacco control trainings before.	1	2	3	4	5	N/A
I feel comfortable speaking in public and training others.	1	2	3	4	5	N/A
I feel anxious just considering idea of training others.	1	2	3	4	5	N/A
When conducting a training, I am afraid attendees will notice that I am nervous.		2	3	4	5	N/A
I have previously received feedback about my ability to conduct trainings.	1	2	3	4	5	N/A
I have received support and encouragement to engage in activities as a trainer/ health educator.	1	2	3	4	5	N/A
I feel confident about answering my colleagues' questions about tobacco control in the context of this training.	1	2	3	4	5	N/A


Items were developed by the TTTF research team for the purpose of this project.


	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate your capacity to conduct a training on tobacco control to members of your organization?	1	2	3	4	5


APPENDIX D


90-MINUTE EMPLOYEE TRAINING SLIDE DECK























APPENDIX D

90-MINUTE EMPLOYEE TRAINING SLIDE DECK (CONTINUED)





















APPENDIX D

90-MINUTE EMPLOYEE TRAINING SLIDE DECK


(CONTINUED)



















APPENDIX D

90-MINUTE EMPLOYEE TRAINING <u>SLIDE DECK</u> (CONTINUED)



E-cigarettes and Electronic Nicotine Delivery Systems Evidence suggests ENDS are less harmful than traditional, combustible cigarettes, but not harmless

Research states:

Presence of toxic substances (ie, fine/ultrafine particles, cytotoxicity, various metals, TSNAs, and carbonyls), but lower levels than cigarettes

Dual use of ENDS & combustible ciga common & is problematic

Not effective method to quit smoking

Long term health consequence of e-cigarette use unknown

Use of ENDS should be discouraged and not be used as a first line cessation method

Long term service in Comparise and Modeline, 2018 And Academies of Storous, Inspirence of e-cigarette use unknown

Use of ENDS should be discouraged and not be used as a first line cessation method









Sustainable Education/Training Program Implementaion Guide | 53

APPENDIX E

PRESENTATION/TEACHING TIPS

What does your audience need to know and want to know?

Have clear objectives and let those guide the direction of the presentation. People want to know why this information is important and what they will be learning.

Be conversational in your approach

Think of your presentation as a discussion with your coworkers. Make eye contact with people as you make your points throughout your talk. You will feel less like you are on stage and it will help you to be conversational in your approach.

Passion for the subject draws the listeners in

You are the champion of the ideas you are presenting. Your enthusiasm for the topic and your energy around the event may be contagious in the best way.

Tell Stories

If you have stories to highlight some of the information you are giving, a story associates that information to the story which raises its importance and makes it easier to remember. Overall, your presentation should be one big story on the topic you are presenting.

Ask Questions

Get the audience involved by asking open-ended questions. Ask what they may already know about a topic you are about to talk about. Ask how this could apply in their specific work setting.

Use Experiential Learning

Small group discussion or role-playing a new skill is a great way to get people involved. Breakouts for experiential learning are a great way to keep learners engaged throughout a presentation.

Use Visual Aids

Visual aids help people retain information and can anchor a point you want to make. Be selective and make sure it is relevant.

Stop for Q & A

Make sure that you take time throughout any training or presentation to stop periodically to check for understanding and discussion of concepts. Some may not feel comfortable asking questions in an interactive way, so it is good to stop and check for comprehension and engagement.

Avoid too much text if using slides

I know, we have so much to say and they have so much to learn! Keep it simple. Slides that are jammed with too many words are less likely to be read. Likewise, if we use font that is too small, we are likely to put too many words on the slide. A picture every now and then breaks up too many words. Remember, you are the expert. Everything you know doesn't have to be on the slide.

Relax and don't forget to smile!

You would be surprised how many people forget to look happy to be presenting. Of course, presenting or teaching can induce nerves. Don't forget that you know more about your presentation than they do.

For more information, see:

https://www.skillsyouneed.com/present/presentation-tips.

https://www.participoll.com/powerpoint-presentation-tips

APPENDIX F

OBSERVER RATING OF PRACTICE INSTRUCTION FEEDBACK FORM

TTTF Observer/Coach: Complete for Actual Training Observation with Agency Attendees

Program Champion Name:

Date:

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
The trainer was knowledgeable about the subject matter.	1	2	3	4	5	N/A
The trainer appeared confident and comfortable with the material.	1	2	3	4	5	N/A
The trainer's ability to explain was excellent.	1	2	3	4	5	N/A
The trainer seemed well prepared for the training.	1	2	3	4	5	N/A
Concrete examples and illustrations were used to clarify the material.	1	2	3	4	5	N/A
The trainer promoted an atmosphere conducive to work and learning.	1	2	3	4	5	N/A
The rate of delivery of material was appropriate.	1	2	3	4	5	N/A
The training was engaging.	1	2	3	4	5	N/A
The trainer listened thoughtfully to attendees' comments and demonstrated empathy and respect.	1	2	3	4	5	N/A
The trainer's eye contact was appropriate.	1	2	3	4	5	N/A
Technology was used without difficulty.	1	2	3	4	5	N/A
Visual training content could be easily read.	1	2	3	4	5	N/A
The trainer's articulation and voice level was clear.	1	2	3	4	5	N/A
The trainer handled attendee questions well.	1	2	3	4	5	N/A
Overall, there was an absence of verbalized pauses (such as er, ah, um).	1	2	3	4	5	N/A

Most items are selected and adapted from C. Roland Christensen, the Center for Teaching and Learning, Harvard Business School (2005, from a peer observation scale used at the University of Minnesota and from items used at the University of Albany

	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate the delivery of the training curriculum by the trainer to setting stakeholders?	1	2	3	4	5
Overall, how would you rate the effectiveness of the trainer as a teacher?	1	2	3	4	5

Please provide any comments that would help to clarify your above ratings.

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.









Sustainable Education/Training Program Implementaion Guide | 55

SAMPLE CERTIFICATE FOR EMPLOYEE ATTENDEES

APPENDIX G

EMPLOYEE ATTENDEES' TOBACCO EDUCATION TRAINING PRE-TEST



THE CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS IN COLLABORATION WITH THE



UNIVERSITY OF HOUSTON AND INTEGRAL CARE

		Tob	acco Dependence	Treatment & Ed	ducation Training Pre/Post T	est
1.	Smoking A.	causes approx 240,000	B. 480,000	deaths a year in C. 640,000	n the United States. D. 840,000	
2.	Which of A. B. C. D. E.	these tobacco Nicotine pa Nicotine in Nicotine lo Nicotine gu All the abo	haler zenge ım	tions requires a	prescription?	PRE TEST
3.		,	nicotine) substance onsume about 40% B. F	of all cigarettes	tal health disorder represent s sold to adults.	about 25% of the United
4.			rventions were ass bstance abuse trea B. 20%		increased likelihood of lo	ong-term alcohol and drug
5.	Which of A.	the following Ask	is <u>NOT</u> one of the B. Arrange	e "Five A's" of t C. Assess	obacco cessation brief interest. D. Allow	vention.
6.	What stre	ngth of nicotii 28 mg	ne patch should be B. 21 mg	used for a perso C. 14 mg	on who is smoking a pack of D. 7 mg	f cigarettes per day?
7.	Behaviora A.	al health treatr lower	nent center employ B. higher	yees have a C. same as	smoking rate that	an the national average.
8.	Which of A.	the following Chantix	tobacco treatment B. Wellbutrii		the most effective in helping otine gum D. Nicotine nasa	
9.	A. la B. be C. be D. be	ck of training elieving it will elieving quittir	on how to address negatively impact	tobacco use a person's reco ossible for peop	le getting clean and sober	
10.		free campus/w at significant A. True		•	nature withdrawal from beh	avioral health treatment
11.	Please ch	eck vour posit	tion:			

APPENDIX H

CERTIFICATE

OF COMPLETION

This Acknowledges That

ATTENDEE NAME

Has Successfully Completed a Hour Training on Tobacco Control and Tobacco Cessation Intervention for Behavioral Health Populations as Delivered By

a Program Champion of the Taking Texas Tobacco Free Program,









A. Provider (provide direct counseling services to clients)

B. General Staff

APPENDIX I

DRUG INTERACTIONS WITH TOBACCO SMOKE



DRUG INTERACTIONS WITH TOBACCO SMOKE

Many interactions between tobacco smoke and medications have been identified. Note that in most cases it is the tobacco smoke—
not the nicotine—that causes these drug interactions. Tobacco smoke interacts with medications through pharmacokinetic (PK) and
pharmacodynamic (PD) mechanisms. PK interactions affect the absorption, distribution, metabolism, or elimination of other drugs,
potentially causing an altered pharmacologic response. The majority of PK interactions with smoking are the result of induction of
hepatic cytochrome P450 enzymes (primarily CYP1A2). PD interactions alter the expected response or actions of other drugs. The
amount of tobacco smoking needed to have an effect has not been established, and the assumption is that any smoker is susceptible
to the same degree of interaction. The most clinically significant interactions are depicted in the shaded rows.

Dendamustine concentrations, with $+$ concentrations of its two active metabolites. A Metabolism (induction of CYP1A2), $+$ clearance (58%). Earlies levels likely $+$ after cessation. A Metabolism (induction of CYP1A2) $+$ clearance (58%). Earlies levels likely $+$ after cessation. A Metabolism (induction of CYP1A2) of clopidogral to its active metabolite. Clopidogral Sefects are enhanced in smokers (7-10 cigaretes/day), significant $+$ platelet inhibition, $+$ platelet inhibition of the platelet inhibition of clops and the platelet inhibition of clops and platelet inhibi	DRUG/CLASS	MECHANISM OF INTERACTION AND EFFECTS
Pendamustine (Treanda) • Metabolized by CYP15A Manufacturer recommends using with caution in smokers due to likely 4-bendamustine concentrations, with 4-concentrations of its two active metabolities. • A Metabolism (induction of CYP162): ↑ clearance (56%). Caffeine levels likely ↑ after cessation. • A Metabolism (induction of CYP162): ↑ clearance (56%). Caffeine levels likely ↑ after cessation. • A Metabolism (induction of CYP162): ↑ clearance (56%). Caffeine levels likely ↑ after cessation. • A Metabolism (induction of CYP162): ↑ clearance (56%). Caffeine levels likely ↑ after cessation. • A Metabolism (induction of CYP162): ↑ clearance (56%). Significant ↑ platelet inhibition, ↓ platelet aggregation; while improved clinical cutcomes have been shown, may also ↑ risk of hierding aggregation; while improved clinical cutcomes have been shown, may also ↑ risk of hierding (Licarante) [Licarante] (Licarante) (Licar	Pharmacokinetic Interaction	ons
Pendamusatine (Treanda) Pendamusatine (Treandamusatine) Pendamusatine (Treandamusatin		
P. ↑ Metabolism (induction of CYP1A2). ↑ clearance (56%). Caffeine levels likely ↑ after cessation. Chiopromazine (Thorazine) Chopidogral (Plavix) - ↑ Area under the curve (ALO (36%) and serum concentrations (24%). - ↑ Metabolism (induction of CYP1A2) of clopidogral to its active metabolite. - Clopidogral (Plavix) - ↑ Metabolism (induction of CYP1A2) of clopidogral to its active metabolite. - Clozapine (Clozarii) - ↑ Metabolism (induction of CYP1A2) of clopidogral to its active metabolite. - ↑ Levies upon cessation may occur; closely monotor drug levels and reduce dose as required to avoid toxicity. - ↑ Evels upon cessation may occur; closely monotor drug levels and reduce dose as required to avoid toxicity. - ↑ Clearance (24%), ↓ brough serum concentrations (21%), ▶ plasma concentrations (24%), ↓ Place (24%), ↑ Clearance (25%), ↑ Clearance (25	Bendamustine (Treanda)	Metabolized by CYP1A2. Manufacturer recommends using with caution in smokers due to likely ✓
. ◆ Area under the curve (AUC) (39%) and serum concentrations (24%). ◆ Sedation and hypotension possible in smokers, smokers may require ↑ dosages. Clopidogrel (Plavix) Clopidogrel Seffects are enhanced in smokers (~10 cigarettes/days, significant ↑ platelet inhibition, ♣ platelet inhibition and platel		
 ↑ Metabolism (induction of CYP1A2) of clopidogrel to its active metabolite. Clopidogrel's effects are enhanced in smokers (*10 cigarettes'day): significant ↑ platelet inhibition, ↓ platelet aggregation, while improved clinical outcomes have been shown, may also ↑ risk of bleeding ↑ Metabolism (induction of CYP1A2) ↓ plasma concentrations (19%) ↑ P. Levels upon cessation may occur; closely monitor drug levels and reduce dose as required to avoid toxicity ↑ Clearance (24%); ↓ trough serum concentrations (25%). Smokers may need ↑ dosages. ↑ P. Clearance (61%); ↓ trough serum concentrations (25%). Smokers may need ↑ dosages. ↑ P. Clearance (61%); ↓ trough serum concentrations (25%). Desage modifications not routinely recommended but smokers may need ↑ dosages. ↑ P. Clearance (44%); ↓ serum concentrations (70%). ↑ P. Servishe ↓ mislum shorphon secondary to perpheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. ↑ P. Clearance (18%); ↓ serum concentrations of active metabolite. SN-38 (~40%, via induction of glucuronidation); ↓ systemic officially significant, smokers may need ↑ dosages. ↑ P. Clearance (18%); ↓ serum concentrations of active metabolite. SN-38 (~40%, via induction of glucuronidation); ↓ systemic exposure resisting in lower hematologic toxicity and may reduce efficacy. ▶ Smokers may need ↑ dosages. ↑ P. Clearance (25%, via oxidation and glucuronidation); ↓ half-life (30%). Dosage modifications not routinely recommended but smokers may need ↑ dosages. ↑ P. Clearance (25%, via oxidation and glucuronidati	Chlorpromazine (Thorazine)	
Clozapine (Clozarii) - Clozapine (Clozarii) - Metabolism (induction of CYP1A2) → plasma concentrations (19%) - Metabolism (induction of CYP1A2) → plasma concentrations (19%) - Metabolism (induction of CYP1A2) → plasma concentrations (19%) - Metabolism (induction of CYP1A2) → plasma concentrations (19%) - Metabolism (induction of CYP1A2) → plasma concentrations (24%) - Metabolism (induction of CYP1A2) → clearance (25%). Smokers may need ↑ dosages. - Metabolism (induction of CYP1A2) → clearance (25%). ★ AUC (31%) → plasma concentrations (32%). - Dosage modifications not routinely recommended but smokers may need ↑ dosages. - Metabolism (induction of CYP1A2) → clearance (25%). ★ AUC (31%) → plasma concentrations (32%). - Dosage modifications not routinely recommended but smokers may need ↑ dosages. - Metabolism unknown but ↑ clearance and → half-life are observed. Smoking has prothrombotic effects. - Smokers may need ↑ dosages. - Possible → insulin absorption secondary to peripheral viasoconstriction, smoking may cause release of endogenous substances that cause insulin resistance. - Price Possible → insulin absorption secondary to peripheral viasoconstriction, smoking may cause release of endogenous substances that cause insulin resistance. - Price Possible → insulin absorption secondary to peripheral viasoconstriction, smoking may cause release of endogenous substances that cause insulin resistance. - Price Possible → insulin absorption secondary to peripheral viasoconstriction, smoking may cause release of endogenous substances that cause insulin resistance. - Price Possible → Price Possible of Possible		
P. Levels upon cessation may occur, closely monitor drug levels and reduce dose as required to avoid toxicity. Eclorinic (Tarceva) P. Clearance (21%), ∀ trough serum concentrations (25%). Smokers may need ↑ dosages. Pluvoxamine (Luvox) P. Metabolism (induction of CYP1A2); ↑ clearance (24%), ↑ AUC (31%), ₺ plasma concentrations (32%). Dosage modifications not routinely recommended but smokers may need ↑ dosages. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking has prothrombotic effects. Smokers may need ↑ dosages due to PK and PD interactions. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may cause release of endogenous substances that cause insulin resistance. Prossible (Mexitil) Prossible ✓ insulin absorption secondary to peripheral vasoconstriction; smoking may reause release of endogenous substances that cause insulin resistance. Propranolal (Indexitil) Program (Vyprexa) Propranolal (Indexitil) Program (Vyprexa) Propranolal (Indexitil) Program (Vyprexa) Pr	Clopidogrei (Plavix)	Clopidogrel's effects are enhanced in smokers (≥10 cigarettes/day): significant ↑ platelet inhibition, ↓ platelet
Elecamide (Tambocor) - ↑ Clearance (61%); ↓ trough serum concentrations (25%), Smokers may need ↑ dosages. - ↑ Metabolism (induction of CYP1A2); ↑ clearance (24%); ↓ AUC (31%), ↓ plasma concentrations (32%). - ↑ Clearance (44%); ↓ serum concentrations (70%). - ↑ Clearance (10%); ↓ serum concentrations (70%). - ↑ ↑ Clearance (10%); ↓ serum concentrations of active metabolite, SN-38 (~40%, via induction of glucurondation); ↓ systemic exposure resulting in lower hematologic toxicity and may reduce efficacy. - ↑ ↑ ↑ ○ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑	Clozapine (Clozaril)	■ ↑ Levels upon cessation may occur; closely monitor drug levels and reduce dose as required to avoid toxicity.
Fluvoxamine (Luvox) - Metabolism (induction of CYP1A2), ↑ clearance (24%); ▶ ALIC (31%); ▶ plasma concentrations (32%). - Dosage modifications not routinely recommended but smokers may need ↑ dosages. - Clearance (44%), ▶ serum concentrations (70%). - Mechanism unknown but ↑ clearance and ▶ nal-life are observed. Smoking has prothrombotic effects. - Smokers may need ↑ dosages due to PK and PD interactions. - PK & PD interactions (and propose). - PK Metabolism (induction of CYP1A2) PC clearance (98%); y serum concentrations (12%). - PK Metabolism (induction of CYP1A2) PK Metabolism	Erlotinib (Tarceva)	↑ Clearance (24%); ↓ trough serum concentrations (2-fold).
Dosage modifications not routinely recommended but smokers may need ↑ dosages.	Flecainide (Tambocor)	 ↑ Clearance (61%);
Mechanism unknown but ↑ clearance and ↓ half-life are observed. Smoking has prothrombotic effects. Smokers may need ↑ dosages due to PK and PD Interactions, smoking may cause release of endogenous substances that cause insulin resistance. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely not clinically significant, smokers may need ↑ dosages. PK & PD Interactions likely significant, smokers may need ↑ dosages. PK & PD Interactions likely significant, smokers may need ↑ dosages. Propranolol (Inderal) PK ← Clearance (25%; via oxidation and glucuronidation); ↓ half-life (36%). Dosage modifications not routinely recommended but smokers may need ↑ dosages. Propranolol (Inderal) PK ← Clearance (75%; via side-chain oxidation and glucuronidation). Propranolol (Inderal) PK ← Clearance (25%; via side-chain oxidation and glucuronidation). Propranolol (Inderal) PK ← Clearance (25%; via side-chain oxidation and glucuronidation). Propranolol (Inderal) PK ← Clearance (25%; via side-chain oxidation and glucuronidation). Propranolol (Inderal) PK ← Clearance (25%; via side-chain oxidation and glucuronidation). PK ← Clearance (25%; via side-chain oxidation and glucuronidation). PK ← Clearance (25%; via side-chain oxidation and glucuronidation). PK ← Clearance (25%; via side-chain oxidation and glucuronidation). PK ← Clearance (25%; via side-chain oxidation and glucuronidation). PK ← Malbolism (induction of CVP1A2). Phalf-life (50%), serum concentrations 3-loid lower. PK ← Malbolism (induction of CVP1A2). Phalf-life (50%), serum concentrations 3-loid lower. PK ← Malbolism (inducti	Fluvoxamine (Luvox)	Dosage modifications not routinely recommended but smokers may need ↑ dosages.
Smokers may need ↑ dosages due to PK and PD interactions.	Haloperidol (Haldol)	
endogenous substances that cause insulin resistance. PK & PD interactions likely not clinically significant, smokers may need ↑ dosages. 1 Cliniotecan (Camptosar) 2 Smokers may need ↑ dosages 2 Cliniotecan (Camptosar) 2 Cliniotecan (Camptosar) 3 Smokers may need ↑ dosages 4 Clearance (25%; via oxidation and glucuronidation); ↓ half-life (30%). 4 Clearance (25%; via oxidation and glucuronidation); ↓ half-life (30%). 5 Dosage modifications not routinely recommended but smokers may need ↑ dosages. Propranolol (Inderal) 4 Clearance (77%; via side-chain oxidation and glucuronidation). 8 Copinirole (Requip) 5 Clearance (77%; via side-chain oxidation and glucuronidation). 8 Copinirole (Requip) 6 Clearance (77%; via side-chain oxidation and glucuronidation). 9 Clearance (77%; via side-chain oxidation and glucuronidation). 9 Clearance (37%; via side-chain oxidation and glucuronidation). 1 Clearance (77%; via side-chain oxidation and glucuronidation). 1 Clearance (77%; via side-chain oxidation and glucuronidation). 1 Clearance (37%; via side-chain oxidation and glucuronidation). 1 Clearance (37%; via side-chain oxidation and glucuronidation). 2 Clearance (37%; via side-chain oxidation and glucuronidation). 3 Clearance via side vi	Heparin	
## Clearance (18%), ↓ serum concentrations of active metabolite, SN-38 (~40%, via induction of glucuronidation), ↓ systemic exposure resulting in lower hematologic toxicity and may reduce efficacy. Smokers may need ↑ dosages ↑ Clearance (25%, via oxidation and glucuronidation), ↓ half-life (36%). ○ The Metabolism (induction of CYP1A2), ↑ clearance (98%); ↓ serum concentrations (12%). ○ Dosage modifications not routinely recommended but smokers may need ↑ dosages. Propranolol (Inderal) ↑ Clearance (77%; via side-chain oxidation and glucuronidation). ↑ Metabolism (induction of CYP1A2); ↑ clearance (58~100%); ↓ half-life (63%). ↑ Levels should be monitiored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers. ↑ Clearance with second-hand smoke exposure. ↑ Metabolism (induction of CYP1A2); ↑ clearance (58~100%); ↓ half-life (63%). ↑ Levels should be monitiored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers. ↑ Clearance with second-hand smoke exposure. ↑ Clearance with second-hand smoke exposure. ↑ Metabolism (induction of CYP1A2); ↑ clearance (58~100%); ↓ half-life (63%). ↑ Metabolism (induction of CYP1A2) of Renantioner, however, Senantioner is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking certain mal	Insulin, subcutaneous	endogenous substances that cause insulin resistance.
Olanzapine (Zyprexa) - ↑ Metabolism (induction of CYP1A2); ↑ clearance (98%); ↓ serum concentrations (12%). Dosage modifications not routinely recommended but smokers may need ↑ dosages. ↑ Clearance (79%; via side-chain oxidation and glucuronidation). • ↓ Cmax (30%) and AUC (38%) in study with patients with restless legs syndrome. Smokers may need ↑ dosages. ↑ Metabolism (induction of CYP1A2), ↓ half-life (50%), serum concentrations 3-fold lower. Smokers may need ↑ dosages. ↑ Metabolism (induction of CYP1A2), ↑ clearance (58~100%); ↓ half-life (63%). Levels should be monitored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers ↑ Clearance with second-hand smoke exposure. Tricyclic antidepressants (e.g., impramine, nortriptyline) Tizandine (Zanaflex) ↑ AUC (30.40%) and ↓ half-life (10%) observed in male smokers. ↑ Metabolism (induction of CYP1A2) of R enantiomer, however, S enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazeprines (diazepam, chlordiazepoxide) Beta blockers ↓ Sedation and drowsiness, possibly caused by nicotine stimulation of central nervous system cativation. Smokers may need ↑ dosages. ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↑ Analgesic effect, smoking may ↑ the metabolism of propoxyphene (15-20%) and pentazocine (40%). Mechanism unknown ▼ Metabolism (induction of CYP1A2) of a part neter.	Irinotecan (Camptosar)	 ↑ Clearance (18%),
Dosage modifications not routinely recommended but smokers may need ↑ dosages. Propranolol (Inderal) ↑ Clearance (77%; via side-chain oxidation and glucuronidation). Ropinirole (Requip) ↑ Clearance (77%; via side-chain oxidation and glucuronidation). ↑ Clearance (77%; via side-chain oxidation and glucuronidation). ↑ Metabolism (induction of CYP1A2), v half-life (50%), serum concentrations 3-fold lower. ↑ Metabolism (induction of CYP1A2), v half-life (50%), serum concentrations 3-fold lower. ↑ Metabolism (induction of CYP1A2), v half-life (63%). ↑ Metabolism (induction of CYP1A2), v half-life (63%). ↑ Clearance with second-hand smoke exposure. ↑ Possible interaction with tricyclic antidepressants in the direction of v blood levels, but the clinical significance is not established. ↑ Metabolism (induction of CYP1A2) of R enantiomer, however, S enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazepines (diazepam, chloridazepoxide) Beta blockers ↑ Sedation and drowsiness, possibly caused by nicotine stimulation of central nervous system citivation. ↑ Smokers may need ↑ dosages. Corticosteroids, inhaled ↑ Smokers may need ↑ dosages. Corticosteroids, inhaled ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑ risk of venous thromboembolism compared to oral contraceptive silkely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. Mechanism unknown ▼ Metabolism compared ↑ opioid dosages for pain relief.	Mexiletine (Mexitil)	↑ Clearance (25%; via oxidation and glucuronidation); ↓ half-life (36%).
Provided (Requip) Pro	Olanzapine (Zyprexa)	
Smokers may need ↑ dosages. ↑ Metabolism (induction of CYP1A2), ↓ half-life (50%), serum concentrations 3-fold lower. Smokers may need ↑ dosages. ↑ Metabolism (induction of CYP1A2), ↑ clearance (58–100%); ↓ half-life (63%). Levels should be monitored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers. ↑ Clearance with second-hand smoke exposure. Tricyclic antidepressants (e.g., mipramine, nortriptyline) Tizanidine (Zanaflex) ↑ AUC (30-40%) and ↓ half-life (10%) observed in male smokers. ↑ Metabolism (induction of CYP1A2) of R enantiomer; however, S enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazepines (diazepam, chlordazepoxide) Beta blockers ↑ Sedation and drowsiness, possibly caused by nicotine stimulation of central nervous system. Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Hormonal contraceptives ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↑ Analgesic effect, smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). Mechanism unknown. Smokers may need ↑ opioid dosages for pain relief.	Propranolol (Inderal)	
↑ Metabolism (induction of CYP1A2), ↓ half-life (50%), serum concentrations 3-fold lower.	Ropinirole (Requip)	
 ↑ Metabolism (induction of CYP1Λ2); ↑ clearance (58–100%); ↓ half-life (63%). Levels should be monitored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers. ↑ Clearance with second-hand smoke exposure. Tricyclic antidepressants (e.g., impramine, nortriptyline) Possible interaction with tricyclic antidepressants in the direction of ↓ blood levels, but the clinical significance is not established. ↓ AUC (30-40%) and ↓ half-life (10%) observed in male smokers. ↑ Metabolism (induction of CYP1Λ2) of R enantiomer; however, S enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazepines (diazepam, chlordiazepoxide) Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Smokers with asthma may have less of a response to inhaled corticosteroids. ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (80% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↓ Analgesic effect; smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). Mechanism unknown. Smokers may need ↑ opioid dosages for pain relief. 	Tacrine (Cognex)	 • Metabolism (induction of CYP1A2), ↓ half-life (50%), serum concentrations 3-fold lower.
 Possible interaction with tricyclic antidepressants in the direction of ↓ blood levels, but the clinical significance is not established. ↓ AUC (30-40%) and ↓ half-life (10%) observed in male smokers. ↑ Metabolism (induction of CYP1A2) of R enantiomer; however, S enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazepines (diazepam, chlordiazepoxide) Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Smokers with asthma may have less of a response to inhaled corticosteroids. ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↓ ∧ Analgesic effect; smoking may ↑ the metabolism of propoxyphene (15-20%) and pentazocine (40%). Mechanism unknown. Smokers may need ↑ opioid dosages for pain relief. 	Theophylline (Theo Dur, etc.)	Levels should be monitored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers.
	Tricyclic antidepressants (e.g., imipramine, nortriptyline)	 Possible interaction with tricyclic antidepressants in the direction of blood levels, but the clinical significance is
is inconclusive. Consider monitoring INR upon smoking cessation. Pharmacodynamic Interactions Benzodiazepines (diazepam, chlordiazepoxide) Beta blockers - Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. - Smokers may need ↑ dosages. Controsteroids, inhaled Hormonal contraceptives - Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). - ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. - ↓ ∧ Analgesic effect; smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). - Smokers may need ↑ opioid dosages for pain relief.	Tizanidine (Zanaflex)	↓ AUC (30-40%) and ↓ half-life (10%) observed in male smokers.
Penzodiazepines (diazepam, chlordiazepoxide) Beta blockers Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Formonal contraceptives A Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↑ Analgesic effect; smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). Mechanism unknown Smokers may need ↑ opioid dosages for pain relief.	Wartarin	
Less effective antihypertensive and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Hormonal contraceptives ∴ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ↑ Analgesic effect; smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). Mechanism unknown ■ Smokers may need ↑ opioid dosages for pain relief.	Pharmacodynamic Interact	tions
activation. Smokers may need ↑ dosages. Corticosteroids, inhaled Hormonal contraceptives A Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). A Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. A Nalgesic effect; smoking may ↑ the metabolism of propoxyphene (15-20%) and pentazocine (40%). Mechanism unknown Smokers may need ↑ opioid dosages for pain relief.	Benzodiazepines (diazepam, chlordiazepoxide)	Sedation and drowsiness, possibly caused by nicotine stimulation of central nervous system.
Smokers with asthma may have less of a response to inhaled corticosteroids. Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels). ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old. ○ A nalgesic effect; smoking may ↑ the metabolism of propoxyphene (15–20%) and pentazocine (40%). Mechanism unknown. Smokers may need ↑ opioid dosages for pain relief.	Beta blockers	activation.
↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels).	Corticosteroids, inhaled	
pentazocine) Mechanism unknown Smokers may need ↑ opioid dosages for pain relief	Hormonal contraceptives	smoke and use oral contraceptives. Ortho Evra patch users shown to have 2-fold ↑risk of venous thromboembolism compared to oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels).
Adapted and updated, from Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet 1999;36:425-438.	Opioids (propoxyphene, pentazocine)	Mechanism unknown
	Adapted and updated, fr	rom Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet 1999;36:425-438.

Copyright © 1999-2014 The Regents of the University of California. All rights reserved.

Sustainable Education/Training Program Implementaion Guide | 57

APPENDIX J

PHARMACOLOGIC PRODUCT GUIDE



PHARMACOLOGIC PRODUCT GUIDE: FDA-APPROVED MEDICATIONS FOR SMOKING CESSATION

1		NICOTINE REPLACE	MENT THERAPY (NRT) FORMULA	TIONS		B	Manager and
	GUM	LOZENGE	TRANSDERMAL PATCH	NASAL SPRAY	ORAL INHALER	Bupropion SR	VARENICLINE
	Nicorette ¹ , ZONNIC ² , Generic OTC 2 mg, 4 mg original, cinnamon, fruit, mint	Nicorette Lozenge,¹ Nicorette Mini Lozenge,¹ Generic OTC 2 mg, 4 mg, cherry, mint	NicoDerm CQ¹, Generic OTC (NicoDerm CQ, generic) Rx (generic) 7 mg, 14 mg, 21 mg (24-hr release)	Nicotrol NS ³ Rx Metered spray 10 mg/mL aqueous solution	Nicotrol Inhaler ³ Rx 10 mg cartridge delivers 4 mg inhaled vapor	Zyban ¹ , Generic Rx 150 mg sustained-release tablet	Chantix ³ Rx 0.5 mg, 1 mg tablet
	Recent (≤ 2 weeks) myocardial infarction Serious underlying arrhythmias Serious or worsening angina pectoris Temporomandibular joint disease Pregnancy⁴ and breastfeeding Adolescents (<18 years)	Recent (≤ 2 weeks) myocardial infarction Serious underlying arrhythmias Serious or worsening angina pectoris Pregnancy⁴ and breastfeeding Adolescents (<18 years)	Recent (≤ 2 weeks) myocardial infarction Serious underlying arrhythmias Serious or worsening angina pectoris Pregnancy⁴ (Rx formulations, category D) and breastfeeding Adolescents (<18 years)	Recent (≤ 2 weeks) myocardial infarction Serious underlying arrhythmias Serious or worsening angina pectoris Underlying chronic nasal disorders (rhinitis, nasal polyps, sinusitis) Severe reactive airway disease Pregnancy⁴ (category D) and breastfeeding Adolescents (<18 years)	Recent (≤ 2 weeks) myocardial infarction Serious underlying arrhythmias Serious or worsening angina pectoris Bronchospastic disease Pregnancy* (category D) and breastfeeding Adolescents (<18 years)	Concomitant therapy with medications/conditions known to lower the seizure threshold Hepatic impairment Pregnancy* (category C) and breastfeeding Adolescents (c18 years) Treatment-emergent neuropsychiatric symptoms*: BOXED WARNING REMOVED 12/2016 Contraindications: Seizure disorder Concomitant bupropion (e.g., Wellbutrin) therapy Current or prior diagnosis of bulimia or anorexia nervosa Simultaneous abrupt discontinuation of alcohol or sedatives/benzodiazepines MAO inhibitors in preceding 14 days; concurrent use of reversible MAO inhibitors	Severe renal impairmen (dosage adjustment is necessary) Pregnancy4 (category C and breastfieeding Adolescents (<18 years) Treatment-emergent neuropsychiatric symptoms ⁵ : BOXED WARNING REMOVE 12/2016
	1st cigarette ≤30 minutes after waking: 4 mg 1st cigarette >30 minutes after waking: 2 mg Weeks 1-6: 1 piece q 1-2 hours Weeks 7-9: 1 piece q 2-4 hours Weeks 10-12: 1 piece q 4-8 hours ■ Maximum, 24 pieces/day ■ Chew each piece slowly ■ Park between cheek and gum when peppery or tingling sensation appears (-15-30 chews) ■ Resume chewing when tingle fades ■ Repeat chewlpark steps until most of the nicotine is gone (tingle does not return; generally 30 min) ■ Park in different areas of mouth ■ No food or beverages 15 minutes before or during use ■ Duration up to 12 weeks	1st cigarette ≤30 minutes after waking: 4 mg 1st cigarette >30 minutes after waking: 2 mg Weeks 1-6: 1 lozenge q 1-2 hours Weeks 7-9: 1 lozenge q 2-4 hours Weeks 10-12: 1 lozenge q 4-8 hours ■ Maximum, 20 lozenges/day ■ Allow to dissolve slowly (20-30 minutes for standard, 10 minutes for min) ■ Nicotine release may cause a warm, fingling sensation ■ Do not chew or swallow ■ Occasionally rotate to different areas of the mouth ■ No food or beverages 15 minutes before or during use ■ Duration: up to 12 weeks	>10 cigarettes/day: 21 mg/day x 4-6 weeks 14 mg/day x 2 weeks 7 mg/day x 2 weeks <10 cigarettes/day: 14 mg/day x 6 weeks 7 mg/day x 2 weeks • Rotate patch application site daily, do not apply a new patch to the same skin site for at least one week • May wear patch for 16 hours if patient experiences sleep disturbances (remove at bedtime) • Duration: 8-10 weeks	1–2 doses/four (8–40 doses/day) One dose = 2 sprays (one in each nostril), each spray delivers 0.5 mg of nicotine to the nasal mucosa Maximum 5 doses/four or 40 doses/day For best results, initially use at least 8 doses/day Do not sniff, swallow, or inhale through the nose as the spray is being administered Duration: 3–6 months	6–16 cartridgea/day Individualize dosing; initially use 1 cartridge q 1–2 hours Bast effects with continuous puffing for 20 minutes Initially use at least 6 cartridges/day Nicotine in cartridge is depleted after 20 minutes of active puffing Inhale into back of throat or puff in short breaths Do NOT inhale into the lungs (like a cigarette) but "puff" as if lighting a pipe Open cartridge retains potency for 24 hours No food or beverages 15 minutes before or during use Duration: 3–6 months	150 mg po q AM x 3 days, then 150 mg po bid Do not exceed 300 mg/day Begin therapy 1–2 weeks prior to quit date Allow at least 8 hours between doses Avoid bedtime dosing to minimize insomnia Dose tapering is not necessary Duratior, 7-12 weeks, with maintenance up to 6 months in selected patients	Days 1–3: 0.5 mg po q Days 4–7: 0.5 mg po b Weeks 2–12: 1 mg po bid Begin therapy 1 week p to quit date Take dose after eating a with a full glass of water Dose tapering is not necossary Dosing adjustment is necossary for patients v severe renal impairment Duration: 12 weeks; an additional 12-week cour may be used in selecter patients May initiate up to 35 day before target quit date 6 may reduce smoking ov 12-week period of treatment prior to quittin and continue treatment an additional 12 weeks

APPENDIX J

PHARMACOLOGIC PRODUCT GUIDE (CONTINUED)

		NICOTINE REPLACE	MENT THERAPY (NRT) FORMULA	TIONS		The second second	No.
	GUM	Lozenge	TRANSDERMAL PATCH	NASAL SPRAY	ORAL INHALER	BUPROPION SR	VARENICLINE
ADVERSE EFFECTS	Mouth/jaw soreness Hiccups Dyspepsia Hypersalivation Effects associated with incorrect chewing technique: Lightheadedness Nauseal/vomiting Throat and mouth irritation	Mouth irritation Nausea Hiccups Heartburn Headache Sore throat Dizziness	Local skin reactions (erythema, pruntus, burning) Headache Sleep disturbances (insomnia, abnormal/vviid dreams); associated with nocturnal nicotine absorption	Nasal and/or throat irritation (hot, peppery, or burning sensation) Rhinitis Tearing Sneezing Cough Headache	Mouth and/or throat irritation Cough Headache Rhinitis Dyspepsia Hiccups	Insomnia Dry mouth Nervousness/difficulty concentrating Nausea Dizziness Constipation Rash Seizures (risk is 0.1%) Neuropsychiatric symptoms (rare: see PRECAUTIONS)	Nausea Sleep disturbances (insomnia, abnormal/vivid dreams) Constipation Flatulence Vomiting Neuropsychiatric symptoms (rare; see PRECAUTIONS)
ADVANTAGES	Might serve as an oral substitute for tobacco Might delay weight gain Can be titrated to manage withdrawal symptoms Can be used in combination with other agents to manage situational urges	Might serve as an oral substitute for tobacco Might delay weight gain Can be utrated to manage withdrawal symptoms Can be used in combination with other agents to manage situational urges	Once-daily dosing associated with fewer adherence problems Of all NRT products, its use is least obvious to others Can be used in combination with other agents, delivers consistent nicotine levels over 24 hours	Can be titrated to rapidly manage withdrawal symptoms Can be used in combination with other agents to manage situational urges	Might serve as an oral substitute for tobacco Can be titrated to manage withdrawal symptoms Mimics hand-to-mouth ritual of smoking Can be used in combination with other agents to manage situational urges	Twice-daily oral dosing is simple and associated with fewer adherence problems Might delay weight gain Might be beneficial in patients with depression Can be used in combination with NRT agents	Twice-daily oral dosing is simple and associated with fewer adherence problems Offers a different mechanism of action for patients who have failed other agents
DISADVANTAGES	Need for frequent dosing can compromise adherence Might be problematic for patients with significant dental work Proper chewing technique is necessary for effectiveness and to minimize adverse effects Gum chewing might not be acceptable or desirable for some patients	Need for frequent dosing can compromise adherence Gastrointestinal side effects (nausea, hiccups, heartburn) might be bothersome	When used as monotherapy, cannot be titrated to acutely manage withdrawal symptoms Not recommended for use by patients with dermatologic conditions (e.g., psoriasis, eczema, atopic dermatitis)	Need for frequent dosing can compromise adherence Nasal administration might not be acceptable or desirable for some patients; nasal irritation often problematic Not recommended for use by patients with chronic nasal disorders or severe reactive airway disease	Need for frequent dosing can compromise adherence Cost of treatment Cartridges might be less effective in cold environments (≤60°F)	Seizure risk is increased Several contraindications and precautions preclude use in some patients (see PRECAUTIONS) Patients should be monitored for potential neuropsychiatric symptoms' (see PRECAUTIONS)	Cost of treatment Patients should be monitored for potential neuropsychiatric symptoms ² (see PRECAUTIONS)
COST/DAY®	2 mg or 4 mg: \$1.90-\$3.60 (9 pieces)	2 mg or 4 mg; \$3.33–\$3.60 (9 pieces)	\$1.52-\$2.90 (1 patch)	\$7.30 (8 doses)	\$12.42 (6 cartridges)	\$2.58-\$8.25 (2 tablets)	\$11.88 (2 tablets)

Abbreviations: MAO, monoamine oxidase; NRT, nicotine replacement therapy; OTC, over-the-counter (nonprescription product); Rx, prescription product. For complete prescribing information and a comprehensive listing of warnings and precautions, please refer to the manufacturers' package inserts.

Copyright © 1999-2017 The Regents of the University of California. All rights reserved. Updated June 8, 2017.

Sustainable Education/Training Program Implementaion Guide | 59

APPENDIX K

PROGRAM CHAMPION SELF-ASSESSMENT PRE-ACTUAL TRAINING SURVEY

Program Champi	ion Self-Assessment	PRE-ACTUAL	TRAINING	DELIVERY
What is your name?				

What LMHA do you work for?

Please rate your level of agreement with the following items:

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
I am a good public speaker.	1	2	3	4	5	N/A
I currently have the capacity to deliver trainings in tobacco control.	1	2	3	4	5	N/A
I have observed others conducting tobacco control trainings before.	1	2	3	4	5	N/A
I feel comfortable speaking in public and training others.	1	2	3	4	5	N/A
I feel anxious just considering the idea of training others.	1	2	3	4	5	N/A
When conducting a training, I am afraid attendees will notice that I am nervous.	1	2	3	4	5	N/A
I have previously received feedback about my ability to conduct trainings.	1	2	3	4	5	N/A
I have received support and encouragement to engage in activities as a trainer/ health educator.	1	2	3	4	5	N/A
I feel confident about answering my colleagues' questions about tobacco control in the context of this training.	1	2	3	4	5	N/A

Items were developed by the TTTF research team for the purpose of this project.

	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate your capacity to conduct a training on tobacco control to members of your organization?	1	2	3	4	5

	Not at all	Just once	Twice	Three times	Several times
Besides the observed practice with the TTTF team, how many times did you practice/rehearse the presentation that you will deliver to members of your organization?	0	1	2	3	4

Marketed by GlaxoSmithKline.

Marketed by Niconovum USA (a subsidiary of Reynolds American, Inc.)

Marketed by Niconovum USA (a subsidiary of Reynolds American, Inc.)

Marketed by Pfizer.

The U.S. Clinical Practice Guideline states that pregnant smokers should be encouraged to quit without medication based on insufficient evidence of effectiveness and theoretical concerns with safety. Pregnant smokers should be offered behavioral counseling interventions that exceed minimal advice to quit.

In July 2009, the FDA mandated that the prescribing information for all bupropion- and varenicline-containing products include a black-boxed warning highlighting the risk of serious neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. Clinicians should advise patients to stop taking varenicline or bupropion SR and contact a health care provider immediately if they experience agitation, depressed mood, or any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior. If treatment is stopped due to neuropsychiatric symptoms, patients should be monitored until the symptoms resolve. Based on results of a mandated clinical trial, the FDA removed this boxed warning in December 2016.

Approximate cost based on the recommended initial dosing for each agent and the wholesale acquisition cost from Red Book Online. Thomson Reuters, June 2017.

APPENDIX L

OBSERVER RATING OF ACTUAL INSTRUCTION FEEDBACK

TTTF Observer/Coach: Complete for Actual Training Observation with Agency Attendees

Program Champion Name:

Date:

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
The trainer was knowledgeable about the subject matter.	1	2	3	4	5	N/A
The trainer appeared confident and comfortable with the material.	1	2	3	4	5	N/A
The trainer's ability to explain was excellent.	1	2	3	4	5	N/A
The trainer seemed well prepared for the training.	1	2	3	4	5	N/A
Concrete examples and illustrations were used to clarify the material.	1	2	3	4	5	N/A
The trainer promoted an atmosphere conducive to work and learning.	1	2	3	4	5	N/A
The rate of delivery of material was appropriate.	1	2	3	4	5	N/A
The training was engaging.	1	2	3	4	5	N/A
The trainer listened thoughtfully to attendees' comments and demonstrated empathy and respect.	1	2	3	4	5	N/A
The trainer's eye contact was appropriate.	1	2	3	4	5	N/A
Technology was used without difficulty.	1	2	3	4	5	N/A
Visual training content could be easily read.	1	2	3	4	5	N/A
The trainer's articulation and voice level was clear.	1	2	3	4	5	N/A
The trainer handled attendee questions well.	1	2	3	4	5	N/A
Overall, there was an absence of verbalized pauses (such as er, ah, um).	1	2	3	4	5	N/A

Most items are selected and adapted from C. Roland Christensen, the Center for Teaching and Learning, Harvard Business School (2005, from a peer observation scale used at the University of Minnesota and from items used at the University of Albany

	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate the delivery of the training curriculum by the trainer to setting stakeholders?	1	2	3	4	5
Overall, how would you rate the effectiveness of the trainer as a teacher?	1	2	3	4	5

Please provide any comments that would help to clarify your above ratings.

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.

Sustainable Education/Training Program Implementaion Guide | 61

APPENDIX M

EMPLOYEE ATTENDEES' POST TEST & RATINGS OF INSTRUCTION SURVEY



11. Please check your position:

A. Provider (provide direct counseling services to clients)

THE CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS IN COLLABORATION WITH THE



UNIVERSITY OF HOUSTON AND INTEGRAL CARE

		Toba	cco Dependence	Treatment & Ed	ucation Training Pre/Post Te	est
1.	Smoking o	causes approxi 240,000	B. 480,000	deaths a year in C. 640,000	the United States. D. 840,000	
2.	Which of A. B. C. D. E.	these tobacco to Nicotine pat Nicotine inh Nicotine loz Nicotine gur All the abov	aler enge n	ions requires a p	rescription?	POST TEST
3.			nicotine) substance asume about 40% B. Fa	of all cigarettes	al health disorder represent a sold to adults.	about 25% of the United
4.			ventions were assortent ventions were assortent B. 20%		_ increased likelihood of lor D. 30%	ng-term alcohol and drug
5.	Which of A.	the following i Ask	s <u>NOT</u> one of the B. Arrange	"Five A's" of to C. Assess	bacco cessation brief interve D. Allow	ention.
6.	What stren	ngth of nicoting 28 mg	e patch should be B. 21 mg	used for a person C. 14 mg	n who is smoking a pack of D. 7 mg	cigarettes per day?
7.	Behaviora A.	l health treatm lower	ent center employ B. higher	rees have a C. same as	smoking rate than	n the national average.
8.	Which of A.	the following t Chantix	obacco treatment B. Wellbutrin		he most effective in helping tine gum D. Nicotine nasal	
9.	A. lac B. be C. be D. be	ck of training of lieving it will i lieving quitting	n how to address negatively impact	tobacco use a person's recov ssible for people	rery e getting clean and sober	
10.		ree campus/wo at significant le A. True		-	ature withdrawal from beha	vioral health treatment

B. General Staff


Sustainable Education/Training Program Implementaion Guide | 63

APPENDIX N

PROGRAM CHAMPION SELF-ASSESSMENT POST TRAINING & RATINGS OF TTTF-CURRICULUM AND TRAINING SURVEY







www.takingtexastobaccofree.com

Employee Attendees' Rating of Instruction Survey

Please rate the trainer on the following items:

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
The trainer was knowledgeable about the subject matter.	1	2	3	4	5	N/A
The trainer appeared confident and comfortable with the material.	1	2	3	4	5	N/A
The trainer's ability to explain was excellent.	1	2	3	4	5	N/A
The trainer seemed well prepared for the training.	1	2	3	4	5	N/A
Concrete examples and illustrations were used to clarify the material.	1	2	3	4	5	N/A
The trainer promoted an atmosphere conducive to work and learning.	1	2	3	4	5	N/A
The rate of delivery of material was appropriate.	1	2	3	4	5	N/A
The training was engaging.	1	2	3	4	5	N/A
The trainer listened thoughtfully to attendees' comments and demonstrated empathy and respect.	1	2	3	4	5	N/A
The trainer's eye contact was appropriate.	1	2	3	4	5	N/A
Technology was used without difficulty.	1	2	3	4	5	N/A
Visual training content could be easily read.	1	2	3	4	5	N/A
The trainer's articulation and voice level was clear.	1	2	3	4	5	N/A
The trainer handled attendee questions well.	1	2	3	4	5	N/A

Most items are selected and adapted from C. Roland Christensen, the Center for Teaching and Learning, Harvard Business School (2005, from a peer observation scale used at the University of Minnesota and from items used at the University of Albany.

	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate the effectiveness of the trainer as a teacher?	1	2	3	4	5

	Extremely Dissatisfied	Dissatisfied	Neutral	Satisfied	Extremely Satisfied
Overall, please rate how satisfied you were with this training.	1	2	3	4	5

This is a two sided document – please turn the page over and complete the other side.

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.









APPENDIX N

PROGRAM CHAMPION SELF-ASSESSMENT POST TRAINING & RATINGS OF TTTF-CURRICULUM AND TRAINING SURVEY (CONTINUED)



☑ @TTTF_
f @TakingTexasTobaccoFree



Please provide any comments that would help to clarify your ratings.

Please discuss the strengths of the training and trainer.

Please provide suggestions for changes or improvement for the training or trainer.

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.









Sustainable Education/Training Program Implementaion Guide | 65

APPENDIX O

PROGRAM CHAMPION SELF-ASSESSMENT POST-TRAINING DELIVERY & TRAINER RATINGS OF TTTF-PROVIDED CURRICULUM AND TRAINING



<pre>@TTTF_</pre>	
@Taking	Texas Tobacco Free

7
\bigcirc taking texas to baccofree @gmail.com
mww.takingtexastobaccofree.com

Program Champion Self-Assessment POST TRAINING DELIVERY

What is your name?	
What center do you work for? _	

Please rate your level of agreement with the following items:

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
I am a good public speaker.	1	2	3	4	5	N/A
I currently have the capacity to deliver trainings in tobacco control.	1	2	3	4	5	N/A
I have observed others conducting tobacco control trainings before.	1	2	3	4	5	N/A
I feel comfortable speaking in public and training others.	1	2	3	4	5	N/A
I feel anxious just considering the idea of training others.	1	2	3	4	5	N/A
When conducting a training, I am afraid attendees will notice that I am nervous.	1	2	3	4	5	N/A
I have previously received feedback about my ability to conduct trainings.	1	2	3	4	5	N/A
I have received support and encouragement to engage in activities as a trainer/ health educator.	1	2	3	4	5	N/A
I feel confident about answering my colleagues' questions about tobacco control in the context of this training.	1	2	3	4	5	N/A

Items were developed by the TTTF research team for the purpose of this project.

	Poor	Fair	Good	Very Good	Excellent
Overall, how would you rate your capacity to conduct a training on tobacco control to members of your organization?	1	2	3	4	5

Trainer Ratings of TTTF-Provided Curriculum and Training

	Extremely Dissatisfied	Dissatisfied	Neutral	Satisfied	Extremely Satisfied
Overall, please rate your satisfaction with curriculum provided to you by the TTTF team.	1	2	3	4	5

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.









APPENDIX O

PROGRAM CHAMPION SELF-ASSESSMENT POST-TRAINING DELIVERY & TRAINER RATINGS OF TTTF-PROVIDED CURRICULUM AND TRAINING (CONTINUED)



☑ @TTTF_
■ TakingTexasTobaccoFree

atakingtexastobaccofree@gmail.com	
www.takingtexastobaccofree.com	

Overall, please rate your satisfaction with training you					
received to implement the curriculum provided to you	4	2	2	4	Е
by the TTTF team.	1	2	3	4	5

Please, below indicate any strengths of the training you received.

Please, below indicate any ways in which the training you received could be improved.

Please, below let us know if you have additional training needs that the TTTF team can help with

Please, provide us with any feedback you would like for us to know.

Copyright © 2020 by Taking Texas Tobacco Free.

A project of Integral Care and the University of Houston, supported by the Cancer Prevention & Research Institute of Texas.









Sustainable Education/Training Program Implementaion Guide | 67

APPENDIX P

PROGRAM CHAMPION SUMMARY SHEET

Taking Texas Tobacco Free and Click here to enter text.

The Taking Texas Tobacco Free (TTTF) program helps behavioral health agencies across the state of Texas to implement a comprehensive program to address tobacco use through education, screening, and treatment, and outreach services at their workplaces.

You recently participated in TTTF's newest initiative targeting tobacco cessation treatment education and its sustainability within the behavioral health agencies we partner with. Ongoing efforts to educate employees on tobacco use outcomes and tobacco cessation treatment is essential in ultimately helping clients and employees become successful in their quit attempts.

As part of this training initiative, Click here to enter text. employees from Click here to enter text. participated in two 1-hour trainings that you delivered on Click here to enter a date. and Click here to enter a date. to learn more about the hazards of tobacco use and how to guide tobacco users in their quit attempts. Training activities included an evaluation of participating employees' knowledge before and after the training, as well as an evaluation of you as a trainer and the training you provided.

Employees trained by Click here to enter text.: Knowledge Gained

Congratulations! Pre- and post-training evaluations revealed Choose an item. in all areas assessed, with about a Click here to enter text. in overall tobacco and tobacco-cessation knowledge.

	Employee Training 1	Employee Training 2	Total Across Trainings
Pre-Training , % Correct			
Post-Training, %			
Correct			
% Change, Pre- to Post-			
Training			

The Impact of your Tobacco Use Treatment Training Efforts at Click here to enter text.

Results suggest that employees at your trainings have increased their awareness of the risks associated with tobacco use and the benefits of becoming tobacco-free. They are in an excellent position to help their clients and colleagues quit tobacco and improve their health and quality of life!

The employees that attended each of your trainings were asked to evaluate the training session as well as your performance as their trainer. On a scale where 1=Poor and 5= Excellent, the employees that attended your first training altogether rated your effectiveness as a teacher as Click here to enter text. and Click here to enter text. of employees were satisfied or extremely satisfied with the training. For your second training session, employees that attended overall rated your effectiveness as a teacher as Click here to enter text. and Click here to enter text. of employees were satisfied or extremely satisfied with the training.

The following are some of the comments that employees provided on your evaluations:

- Click here to enter text.
- Click here to enter text.
- Click here to enter text.

APPENDIX P

PROGRAM CHAMPION SUMMARY SHEET (CONTINUED)

- Click here to enter text.
- Click here to enter text.

Every employee has a role to play in making Click here to enter text. a tobacco-free environment and supporting tobacco-using clients, and we deeply appreciate all the training and work that you have done to support this effort.

Please continue to educate your employees in order to support your tobacco-using clients in their quit attempts and continued recovery from tobacco use. We are continually adding training materials and resources on our website under the "<u>Train the Trainer</u>" section that will assist you in ongoing tobacco control education efforts at your center, so make sure to check back in often!



APPENDIX Q

SAMPLE CERTIFICATE FOR PROGRAM CHAMPION



APPENDIX R

PROGRAM CHAMPION RATINGS OF TTTF-CURRICULUM INTERVIEW GUIDE

CPRIT TOBACCO EDUCATION GRANT BY THE UNIVERSITY OF HOUSTON AND INTEGRAL CARE

Program Champion Post-Implementation Interview Guide

- 1. Tell us about what was good about the training you received.
- 2. Tell us about what could be improved about the training you received.
- 3. Tell us about what was good about the education/curriculum materials you received for your training.
- 4. Tell us about what could be improved about the education/curriculum materials you received for your training.
- 5. What additional training needs do you have that the TTTF team can help with?
- 6. Our aim is to provide you with effective and comprehensive training to ensure that you can confidently train others in your organization regarding tobacco use and treatment. Can you tell me how confident you feel in delivering tobacco trainings to others in your organization?
- 7. What else do you need to deliver these trainings effectively within your organization? (i.e. resources, interdepartmental/organizational cooperation and planning)
- 8. We are going to make the curriculum and materials online for other centers to use. What do you think we might need to change or otherwise provide to make these materials as helpful as possible to those who did not receive the hands-on training you received?
- 9. What else would you like for the TTTF team to know?

Closing: Thank you so much for your time and for sharing your thoughts today.

59







■ @TTTF_ **f** @TakingTexasTobaccoFree www.takingtexastobaccofree.com







